



Clinical trial results:

A PHASE 1A/1B, MULTICENTER, OPEN LABEL, DOSE-FINDING STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF THE DUAL DNA-PK AND TOR KINASE INHIBITOR, CC-115, ADMINISTERED ORALLY TO SUBJECTS WITH ADVANCED SOLID TUMORS AND HEMATOLOGIC MALIGNANCIES

Summary

EudraCT number	2011-004558-24
Trial protocol	ES FR
Global end of trial date	12 March 2021

Results information

Result version number	v1 (current)
This version publication date	20 March 2022
First version publication date	20 March 2022

Trial information

Trial identification

Sponsor protocol code	CC-115-ST-001
-----------------------	---------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Bristol-Myers Squibb
Sponsor organisation address	Chaussée de la Hulpe 185, Brussels, Belgium, 1170
Public contact	EU Study Start-Up Unit, Bristol-Myers Squibb International Corporation, Clinical.Trials@bms.com
Scientific contact	Bristol-Myers Squibb Study Director, Bristol-Myers Squibb, Clinical.Trials@bms.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	25 June 2021
Is this the analysis of the primary completion data?	No
Global end of trial reached?	Yes
Global end of trial date	12 March 2021
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To determine the safety and tolerability of CC-115 when administered orally and to determine the pharmacokinetics (PK) of CC-115.

Protection of trial subjects:

The study was in compliance with the ethical principles derived from the Declaration of Helsinki and in compliance with all International Conference on Harmonization Good Clinical Practice Guidelines. All the local regulatory requirements pertinent to safety of trial participants were followed.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	25 April 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	France: 6
Country: Number of subjects enrolled	Germany: 3
Country: Number of subjects enrolled	Spain: 15
Country: Number of subjects enrolled	United States: 94
Worldwide total number of subjects	118
EEA total number of subjects	24

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	88
From 65 to 84 years	30

85 years and over	0
-------------------	---

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

118 participants were treated. 44 participants were treated in Part A, 74 participants were treated in Part B

Period 1

Period 1 title	Dose Escalation + Dose Expansion (overall period)
Is this the baseline period?	Yes
Allocation method	Non-randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	QD 0.5 mg

Arm description:

CC-115 administered once a day at a dose of 0.5 mg

Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

0.5 mg QD (once a day)

Arm title	QD 1 mg
------------------	---------

Arm description:

CC-115 administered once a day at a dose of 1 mg

Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

1 mg QD (once a day)

Arm title	QD 2 mg
------------------	---------

Arm description:

CC-115 administered once a day at a dose of 2 mg

Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

2 mg QD (once a day)

Arm title	QD 4 mg
Arm description: CC-115 administered once a day at a dose of 4 mg	
Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 4 mg QD (once a day)	
Arm title	QD 8 mg
Arm description: CC-115 administered once a day at a dose of 8 mg	
Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 8 mg QD (once a day)	
Arm title	QD 16 mg
Arm description: CC-115 administered once a day at a dose of 16 mg	
Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 16 mg QD (once a day)	
Arm title	QD 25 mg
Arm description: CC-115 administered once a day at a dose of 25 mg	
Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 25 mg QD (once a day)	
Arm title	QD 40 mg
Arm description: CC-115 administered once a day at a dose of 40 mg	
Arm type	Experimental

Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 40 mg QD (once a day)	
Arm title	BID 10 mg
Arm description: CC-115 administered twice a day at a dose of 10 mg	
Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 10 mg BID (twice a day)	
Arm title	BID 15 mg
Arm description: CC-115 administered twice a day at a dose of 15 mg	
Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 15 mg BID (twice a day)	
Arm title	Dose Expansion cohort - HNSCC
Arm description: Participants diagnosed with Head and Neck Squamous Cell Carcinoma (HNSCC). CC-115 administered twice a day at a dose of 10 mg	
Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details: 10 mg BID (twice a day)	
Arm title	Dose Expansion cohort - GBM
Arm description: Participants diagnosed with Glioblastoma Multiforme (GBM). CC-115 administered twice a day at a dose of 10 mg	
Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

10 mg BID (twice a day)

Arm title	Dose Expansion cohort - CLL/SLL
------------------	---------------------------------

Arm description:

Participants diagnosed with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). CC-115 administered twice a day at a dose of 10 mg

Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

10 mg BID (twice a day)

Arm title	Dose Expansion cohort - CRPC
------------------	------------------------------

Arm description:

Participants diagnosed with Castration-Resistant Prostate Cancer (CRPC). CC-115 administered twice a day at a dose of 10 mg

Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

10 mg BID (twice a day)

Arm title	Dose Expansion cohort - ES
------------------	----------------------------

Arm description:

Participants diagnosed with Ewing's sarcoma (ES). CC-115 administered twice a day at a dose of 10 mg

Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

10 mg BID (twice a day)

Arm title	Dose Expansion cohort - BA/Food Effect
------------------	--

Arm description:

Participants diagnosed with any tumor type and who were treated in the bioavailability(BA)/food effect substudy. CC-115 administered under fasted or fed conditions at 10 mg dose

Arm type	Experimental
Investigational medicinal product name	CC-115
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:
10 mg under fasted or fed conditions

Number of subjects in period 1	QD 0.5 mg	QD 1 mg	QD 2 mg
Started	1	1	1
Completed	0	0	0
Not completed	1	1	1
Adverse event, serious fatal	-	-	-
Physician decision	-	-	-
Consent withdrawn by subject	-	-	-
Disease progression	1	1	1
Adverse event, non-fatal	-	-	-
Other reasons	-	-	-

Number of subjects in period 1	QD 4 mg	QD 8 mg	QD 16 mg
Started	4	6	6
Completed	0	0	0
Not completed	4	6	6
Adverse event, serious fatal	-	-	-
Physician decision	-	-	1
Consent withdrawn by subject	-	-	-
Disease progression	3	6	5
Adverse event, non-fatal	1	-	-
Other reasons	-	-	-

Number of subjects in period 1	QD 25 mg	QD 40 mg	BID 10 mg
Started	7	6	6
Completed	0	0	0
Not completed	7	6	6
Adverse event, serious fatal	1	-	-
Physician decision	-	-	-
Consent withdrawn by subject	1	1	1
Disease progression	4	2	4
Adverse event, non-fatal	1	-	-
Other reasons	-	3	1

Number of subjects in period 1	BID 15 mg	Dose Expansion cohort - HNSCC	Dose Expansion cohort - GBM
Started	6	18	14
Completed	0	0	0
Not completed	6	18	14
Adverse event, serious fatal	-	1	-
Physician decision	-	-	-
Consent withdrawn by subject	2	3	2
Disease progression	3	10	8
Adverse event, non-fatal	1	-	3
Other reasons	-	4	1

Number of subjects in period 1	Dose Expansion cohort - CLL/SLL	Dose Expansion cohort - CRPC	Dose Expansion cohort - ES
Started	8	12	10
Completed	0	0	0
Not completed	8	12	10
Adverse event, serious fatal	-	-	-
Physician decision	-	-	-
Consent withdrawn by subject	-	1	1
Disease progression	4	5	9
Adverse event, non-fatal	2	5	-
Other reasons	2	1	-

Number of subjects in period 1	Dose Expansion cohort - BA/Food Effect
Started	12
Completed	0
Not completed	12
Adverse event, serious fatal	1
Physician decision	-
Consent withdrawn by subject	2
Disease progression	6
Adverse event, non-fatal	-
Other reasons	3

Baseline characteristics

Reporting groups

Reporting group title	QD 0.5 mg
Reporting group description: CC-115 administered once a day at a dose of 0.5 mg	
Reporting group title	QD 1 mg
Reporting group description: CC-115 administered once a day at a dose of 1 mg	
Reporting group title	QD 2 mg
Reporting group description: CC-115 administered once a day at a dose of 2 mg	
Reporting group title	QD 4 mg
Reporting group description: CC-115 administered once a day at a dose of 4 mg	
Reporting group title	QD 8 mg
Reporting group description: CC-115 administered once a day at a dose of 8 mg	
Reporting group title	QD 16 mg
Reporting group description: CC-115 administered once a day at a dose of 16 mg	
Reporting group title	QD 25 mg
Reporting group description: CC-115 administered once a day at a dose of 25 mg	
Reporting group title	QD 40 mg
Reporting group description: CC-115 administered once a day at a dose of 40 mg	
Reporting group title	BID 10 mg
Reporting group description: CC-115 administered twice a day at a dose of 10 mg	
Reporting group title	BID 15 mg
Reporting group description: CC-115 administered twice a day at a dose of 15 mg	
Reporting group title	Dose Expansion cohort - HNSCC
Reporting group description: Participants diagnosed with Head and Neck Squamous Cell Carcinoma (HNSCC). CC-115 administered twice a day at a dose of 10 mg	
Reporting group title	Dose Expansion cohort - GBM
Reporting group description: Participants diagnosed with Glioblastoma Multiforme (GBM). CC-115 administered twice a day at a dose of 10 mg	
Reporting group title	Dose Expansion cohort - CLL/SLL
Reporting group description: Participants diagnosed with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). CC-115 administered twice a day at a dose of 10 mg	
Reporting group title	Dose Expansion cohort - CRPC
Reporting group description: Participants diagnosed with Castration-Resistant Prostate Cancer (CRPC). CC-115 administered twice a day at a dose of 10 mg	
Reporting group title	Dose Expansion cohort - ES
Reporting group description: Participants diagnosed with Ewing's sarcoma (ES). CC-115 administered twice a day at a dose of 10 mg	

Reporting group title	Dose Expansion cohort - BA/Food Effect
Reporting group description:	
Participants diagnosed with any tumor type and who were treated in the bioavailability(BA)/food effect substudy. CC-115 administered under fasted or fed conditions at 10 mg dose	

Reporting group values	QD 0.5 mg	QD 1 mg	QD 2 mg
Number of subjects	1	1	1
Age Categorical			
Units: Subjects			
Adults (18-64 years)	0	1	1
From 65-84 years	1	0	0
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	73.0	58.0	57.0
standard deviation	± 99999	± 99999	± 99999
Gender Categorical			
Units: Subjects			
Female	1	0	0
Male	0	1	1
Race			
Units: Subjects			
Asian	0	0	1
Black or African American	0	0	0
White	1	1	0
Other	0	0	0
Ethnicity			
Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	1	1	1

Reporting group values	QD 4 mg	QD 8 mg	QD 16 mg
Number of subjects	4	6	6
Age Categorical			
Units: Subjects			
Adults (18-64 years)	3	6	5
From 65-84 years	1	0	1
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	49.8	49.5	47.0
standard deviation	± 15.76	± 18.92	± 18.69
Gender Categorical			
Units: Subjects			
Female	3	2	4
Male	1	4	2
Race			
Units: Subjects			
Asian	1	1	3
Black or African American	0	0	1

White	3	5	2
Other	0	0	0
Ethnicity Units: Subjects			
Hispanic or Latino	1	0	0
Not Hispanic or Latino	3	6	6

Reporting group values	QD 25 mg	QD 40 mg	BID 10 mg
Number of subjects	7	6	6
Age Categorical Units: Subjects			
Adults (18-64 years)	7	4	4
From 65-84 years	0	2	2
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	47.3	60.3	59.3
standard deviation	± 15.27	± 8.73	± 10.60
Gender Categorical Units: Subjects			
Female	4	3	3
Male	3	3	3
Race Units: Subjects			
Asian	1	0	0
Black or African American	0	1	0
White	5	5	6
Other	1	0	0
Ethnicity Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	7	6	6

Reporting group values	BID 15 mg	Dose Expansion cohort - HNSCC	Dose Expansion cohort - GBM
Number of subjects	6	18	14
Age Categorical Units: Subjects			
Adults (18-64 years)	3	15	13
From 65-84 years	3	3	1
85 years and over	0	0	0
Age Continuous Units: years			
arithmetic mean	62.2	56.0	53.0
standard deviation	± 8.91	± 10.47	± 10.04
Gender Categorical Units: Subjects			
Female	5	5	4
Male	1	13	10

Race			
Units: Subjects			
Asian	0	0	0
Black or African American	0	0	1
White	6	18	12
Other	0	0	1
Ethnicity			
Units: Subjects			
Hispanic or Latino	0	3	3
Not Hispanic or Latino	6	15	11

Reporting group values	Dose Expansion cohort - CLL/SLL	Dose Expansion cohort - CRPC	Dose Expansion cohort - ES
Number of subjects	8	12	10
Age Categorical			
Units: Subjects			
Adults (18-64 years)	7	3	10
From 65-84 years	1	9	0
85 years and over	0	0	0
Age Continuous			
Units: years			
arithmetic mean	58.4	67.8	36.6
standard deviation	± 7.69	± 5.89	± 12.86
Gender Categorical			
Units: Subjects			
Female	3	0	2
Male	5	12	8
Race			
Units: Subjects			
Asian	0	0	0
Black or African American	0	0	0
White	8	12	10
Other	0	0	0
Ethnicity			
Units: Subjects			
Hispanic or Latino	0	0	0
Not Hispanic or Latino	8	12	10

Reporting group values	Dose Expansion cohort - BA/Food Effect	Total	
Number of subjects	12	118	
Age Categorical			
Units: Subjects			
Adults (18-64 years)	6	88	
From 65-84 years	6	30	
85 years and over	0	0	
Age Continuous			
Units: years			
arithmetic mean	60.8	-	
standard deviation	± 11.53	-	

Gender Categorical			
Units: Subjects			
Female	8	47	
Male	4	71	
Race			
Units: Subjects			
Asian	0	7	
Black or African American	1	4	
White	10	104	
Other	1	3	
Ethnicity			
Units: Subjects			
Hispanic or Latino	0	7	
Not Hispanic or Latino	12	111	

End points

End points reporting groups

Reporting group title	QD 0.5 mg
Reporting group description: CC-115 administered once a day at a dose of 0.5 mg	
Reporting group title	QD 1 mg
Reporting group description: CC-115 administered once a day at a dose of 1 mg	
Reporting group title	QD 2 mg
Reporting group description: CC-115 administered once a day at a dose of 2 mg	
Reporting group title	QD 4 mg
Reporting group description: CC-115 administered once a day at a dose of 4 mg	
Reporting group title	QD 8 mg
Reporting group description: CC-115 administered once a day at a dose of 8 mg	
Reporting group title	QD 16 mg
Reporting group description: CC-115 administered once a day at a dose of 16 mg	
Reporting group title	QD 25 mg
Reporting group description: CC-115 administered once a day at a dose of 25 mg	
Reporting group title	QD 40 mg
Reporting group description: CC-115 administered once a day at a dose of 40 mg	
Reporting group title	BID 10 mg
Reporting group description: CC-115 administered twice a day at a dose of 10 mg	
Reporting group title	BID 15 mg
Reporting group description: CC-115 administered twice a day at a dose of 15 mg	
Reporting group title	Dose Expansion cohort - HNSCC
Reporting group description: Participants diagnosed with Head and Neck Squamous Cell Carcinoma (HNSCC). CC-115 administered twice a day at a dose of 10 mg	
Reporting group title	Dose Expansion cohort - GBM
Reporting group description: Participants diagnosed with Glioblastoma Multiforme (GBM). CC-115 administered twice a day at a dose of 10 mg	
Reporting group title	Dose Expansion cohort - CLL/SLL
Reporting group description: Participants diagnosed with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). CC-115 administered twice a day at a dose of 10 mg	
Reporting group title	Dose Expansion cohort - CRPC
Reporting group description: Participants diagnosed with Castration-Resistant Prostate Cancer (CRPC). CC-115 administered twice a day at a dose of 10 mg	
Reporting group title	Dose Expansion cohort - ES
Reporting group description: Participants diagnosed with Ewing's sarcoma (ES). CC-115 administered twice a day at a dose of 10 mg	

Reporting group title	Dose Expansion cohort - BA/Food Effect
Reporting group description:	
Participants diagnosed with any tumor type and who were treated in the bioavailability(BA)/food effect substudy. CC-115 administered under fasted or fed conditions at 10 mg dose	
Subject analysis set title	Bioavailability/Food Effect Cohort - fasting - capsule
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants in the Dose expansion cohort - BA/Food Effect under fasted conditions - capsule formulation	
Subject analysis set title	Bioavailability/Food Effect Cohort - fasting - tablet
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants in the Dose expansion cohort - BA/Food Effect under fasted conditions - tablet formulation	
Subject analysis set title	Bioavailability/Food Effect Cohort - fed
Subject analysis set type	Sub-group analysis
Subject analysis set description:	
Participants in the Dose expansion cohort - BA/Food Effect under fed conditions - tablet formulation	

Primary: Number of Participants Experiencing Dose-Limiting Toxicity (DLT)

End point title	Number of Participants Experiencing Dose-Limiting Toxicity (DLT) ^{[1][2]}
End point description:	
Dose-Limiting Toxicity is defined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4. Briefly, a DLT is any: - clinically relevant AE \geq grade 3 that is suspected to be related to CC-115 and that commences within 28 days of first dose (with some exceptions). - Clinically relevant laboratory abnormality that is suspected to be related to CC-115 and that commences within 28 days of first dose (Cycle 1) and is \geq grade 3, or any grade 4 laboratory abnormality that is suspected to be related to CC-115 regardless of clinical relevance. - Hyperglycemia meeting specific criteria. - Hematological toxicities meeting specific criteria. - Any AE suspected to be CC-115 related and necessitating dose reduction during Cycle 1.	
End point type	Primary
End point timeframe:	
From first dose up to 28 days after first dose	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed for this endpoint

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was not evaluated in all the cohorts

End point values	QD 0.5 mg	QD 1 mg	QD 2 mg	QD 4 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	3
Units: Participants	0	0	0	0

End point values	QD 8 mg	QD 16 mg	QD 25 mg	QD 40 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	6	5
Units: Participants	0	1	1	2

End point values	BID 10 mg	BID 15 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	6	6		
Units: Participants	0	2		

Statistical analyses

No statistical analyses for this end point

Primary: Maximum Observed Concentration (Cmax)

End point title	Maximum Observed Concentration (Cmax) ^{[3][4]}
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Day 1 and Cycle 1 Day 15

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed for this endpoint

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was not evaluated in all the cohorts

End point values	QD 0.5 mg	QD 1 mg	QD 2 mg	QD 4 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	4
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Cycle 1 Day 1	8.70 (± 99999)	9.32 (± 99999)	10.41 (± 99999)	28.49 (± 19.3)
Cycle 1 Day 15	8.65 (± 99999)	8.11 (± 99999)	13.16 (± 99999)	30.51 (± 81.4)

End point values	QD 8 mg	QD 16 mg	QD 25 mg	QD 40 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	7	6
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Cycle 1 Day 1	36.07 (± 29.4)	88.68 (± 72.6)	173.45 (± 27.9)	167.42 (± 53.3)
Cycle 1 Day 15	40.93 (± 25.6)	118.22 (± 87.0)	197.87 (± 40.4)	243.64 (± 49.1)

End point values	BID 10 mg	BID 15 mg	Dose Expansion cohort - HNSCC	Dose Expansion cohort - CRPC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	8	7
Units: ng/mL				
geometric mean (geometric coefficient of variation)				
Cycle 1 Day 1	51.80 (± 22.8)	133.98 (± 43.5)	42.39 (± 69.75)	66.17 (± 33.10)
Cycle 1 Day 15	75.24 (± 45.2)	161.99 (± 42.8)	68.66 (± 43.17)	112.41 (± 45.70)

Statistical analyses

No statistical analyses for this end point

Primary: Maximum Observed Concentration (Cmax) - BA/Food Effect Cohort

End point title	Maximum Observed Concentration (Cmax) - BA/Food Effect Cohort ^[5]
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Period 1 Day 1, Period 2 Day 1, Period 3 Day 1

Notes:

[5] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed for this endpoint

End point values	Bioavailability/ Food Effect Cohort - fasting - capsule	Bioavailability/ Food Effect Cohort - fasting - tablet	Bioavailability/ Food Effect Cohort - fed	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	4	4	4	
Units: ug/L				
geometric mean (geometric coefficient of variation)				
Period 1 Day 1	91.12 (± 61.59)	50.12 (± 75.90)	55.82 (± 39.55)	
Period 2 Day 1	84.48 (± 68.17)	75.33 (± 69.94)	35.90 (± 49.39)	
Period 3 Day 1	73.73 (± 92.36)	122.49 (± 26.22)	49.15 (± 31.25)	

Statistical analyses

No statistical analyses for this end point

Primary: Area Under the Concentration-Time Curve (AUC)

End point title	Area Under the Concentration-Time Curve (AUC) ^{[6][7]}
-----------------	---

End point description:

Multiple AUC (0 to X hours) were determined and are presented here. Results reported represent data collection at Cycle 1 Day 15 for AUC8, AUC12, AUC24 and AUCt. Results reported represent data collection at Cycle 1 Day 1 for AUC-inf.

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Day 1 and Cycle 1 Day 15

Notes:

[6] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed for this endpoint

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was not evaluated in all the cohorts

End point values	QD 0.5 mg	QD 1 mg	QD 2 mg	QD 4 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	4
Units: ng*h/mL				
geometric mean (geometric coefficient of variation)				
AUC8	42.18 (± 99999)	47.39 (± 99999)	60.03 (± 99999)	169.13 (± 70.2)
AUC12	53.21 (± 99999)	65.79 (± 99999)	72.95 (± 99999)	234.18 (± 62.8)
AUC24	72.31 (± 99999)	108.37 (± 99999)	94.28 (± 99999)	350.11 (± 62.9)
AUC-inf	76.15 (± 99999)	93.07 (± 99999)	57.45 (± 99999)	236.90 (± 48.4)
AUCt	72.31 (± 99999)	108.37 (± 99999)	94.28 (± 99999)	350.11 (± 62.9)

End point values	QD 8 mg	QD 16 mg	QD 25 mg	QD 40 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	7	6
Units: ng*h/mL				
geometric mean (geometric coefficient of variation)				
AUC8	181.82 (± 47.6)	588.01 (± 115.0)	943.05 (± 52.8)	1285.54 (± 42.6)
AUC12	220.74 (± 57.1)	757.98 (± 129.7)	1180.32 (± 57.8)	1732.76 (± 40.3)
AUC24	285.56 (± 73.6)	1094.97 (± 149.0)	1573.20 (± 67.0)	2650.16 (± 36.9)
AUC-inf	237.47 (± 64.1)	624.86 (± 81.7)	1912.20 (± 92.1)	2129.67 (± 45.3)
AUCt	285.56 (± 73.6)	1094.97 (± 149.0)	1573.20 (± 67.0)	2650.16 (± 36.9)

End point values	BID 10 mg	BID 15 mg	Dose Expansion cohort - HNSCC	Dose Expansion cohort - CRPC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	8	6
Units: ng*h/mL				
geometric mean (geometric coefficient of variation)				
AUC8	304.37 (± 35.8)	802.75 (± 53.7)	337.52 (± 62.17)	547.19 (± 62.77)
AUC12	383.04 (± 43.4)	1027.96 (± 55.7)	374.29 (± 32.71)	780.04 (± 65.58)
AUC24	766.07 (± 43.4)	2055.93 (± 55.7)	99999 (± 99999)	99999 (± 99999)
AUC-inf	605.32 (± 60.7)	1306.58 (± 48.4)	99999 (± 99999)	99999 (± 99999)
AUCt	506.67 (± 53.2)	1657.68 (± 64.8)	374.29 (± 32.71)	780.04 (± 65.58)

Statistical analyses

No statistical analyses for this end point

Primary: Area Under the Concentration-Time Curve (AUCinf) - BA/Food Effect Cohort

End point title	Area Under the Concentration-Time Curve (AUCinf) - BA/Food Effect Cohort ^[8]
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Period 1 Day 1, Period 2 Day 1, Period 3 Day 1

Notes:

[8] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed for this endpoint

End point values	Bioavailability/ Food Effect Cohort - fasting - capsule	Bioavailability/ Food Effect Cohort - fasting - tablet	Bioavailability/ Food Effect Cohort - fed	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	4	4	4	
Units: h*ug/L				
geometric mean (geometric coefficient of variation)				
Period 1 Day 1	870.20 (± 79.06)	505.24 (± 155.44)	585.96 (± 96.77)	

Period 2 Day 1	621.70 (\pm 115.72)	832.46 (\pm 75.74)	720.13 (\pm 3.87)	
Period 3 Day 1	1023.01 (\pm 65.26)	725.24 (\pm 79.47)	666.99 (\pm 99999)	

Statistical analyses

No statistical analyses for this end point

Primary: Time to Maximum Concentration (Tmax)

End point title	Time to Maximum Concentration (Tmax) ^[9] ^[10]
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Day 1 and Cycle 1 Day 15

Notes:

[9] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed for this endpoint

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was not evaluated in all the cohorts

End point values	QD 0.5 mg	QD 1 mg	QD 2 mg	QD 4 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	4
Units: hr				
arithmetic mean (standard deviation)				
Cycle 1 Day 1	0.52 (\pm 99999)	3.00 (\pm 99999)	1.50 (\pm 99999)	1.76 (\pm 0.876)
Cycle 1 Day 15	1.50 (\pm 99999)	1.67 (\pm 99999)	2.13 (\pm 99999)	3.36 (\pm 3.165)

End point values	QD 8 mg	QD 16 mg	QD 25 mg	QD 40 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	7	6
Units: hr				
arithmetic mean (standard deviation)				
Cycle 1 Day 1	1.92 (\pm 1.530)	2.44 (\pm 0.940)	2.67 (\pm 1.258)	2.50 (\pm 1.478)
Cycle 1 Day 15	1.92 (\pm 1.004)	2.04 (\pm 0.826)	1.61 (\pm 0.829)	3.02 (\pm 0.044)

End point values	BID 10 mg	BID 15 mg	Dose Expansion cohort - HNSCC	Dose Expansion cohort - CRPC
------------------	-----------	-----------	-------------------------------	------------------------------

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	8	7
Units: hr				
arithmetic mean (standard deviation)				
Cycle 1 Day 1	2.11 (± 0.998)	4.88 (± 9.215)	1.714 (± 0.9512)	1.571 (± 0.6726)
Cycle 1 Day 15	1.55 (± 0.677)	1.83 (± 0.684)	2.250 (± 1.3363)	2.000 (± 1.5000)

Statistical analyses

No statistical analyses for this end point

Primary: Time to Maximum Concentration (Tmax) - BA/Food Effect Cohort

End point title	Time to Maximum Concentration (Tmax) - BA/Food Effect Cohort ^[11]
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Period 1 Day 1, Period 2 Day 1, Period 3 Day 1

Notes:

[11] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed for this endpoint

End point values	Bioavailability/ Food Effect Cohort - fasting - capsule	Bioavailability/ Food Effect Cohort - fasting - tablet	Bioavailability/ Food Effect Cohort - fed	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	4	4	4	
Units: hr				
arithmetic mean (standard deviation)				
Period 1 Day 1	1.875 (± 0.2500)	2.375 (± 0.7500)	3.000 (± 1.4142)	
Period 2 Day 1	1.875 (± 0.8539)	1.500 (± 0.4082)	9.000 (± 10.0995)	
Period 3 Day 1	2.250 (± 0.8660)	0.875 (± 0.4787)	6.500 (± 3.0000)	

Statistical analyses

No statistical analyses for this end point

Primary: Terminal Half-Life (t_{1/2})

End point title	Terminal Half-Life (t _{1/2}) ^{[12][13]}
-----------------	--

End point description:

End point type	Primary			
End point timeframe:				
Cycle 1 Day 1				
Notes:				
[12] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.				
Justification: No statistical analyses were performed for this endpoint				
[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.				
Justification: This endpoint was not evaluated in all the cohorts				
End point values	QD 0.5 mg	QD 1 mg	QD 2 mg	QD 4 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	4
Units: hr				
arithmetic mean (standard deviation)	11.93 (± 99999)	10.60 (± 99999)	6.17 (± 99999)	6.61 (± 1.145)

End point values	QD 8 mg	QD 16 mg	QD 25 mg	QD 40 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	6	6	5
Units: hr				
arithmetic mean (standard deviation)	6.33 (± 2.098)	7.63 (± 2.718)	8.55 (± 4.264)	7.96 (± 3.509)

End point values	BID 10 mg	BID 15 mg	Dose Expansion cohort - HNSCC	Dose Expansion cohort - CRPC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	5	5	6
Units: hr				
arithmetic mean (standard deviation)	4.04 (± 0.827)	5.68 (± 2.748)	3.478 (± 2.0857)	4.426 (± 1.6685)

Statistical analyses

No statistical analyses for this end point

Primary: Terminal Half-Life (t_{1/2}) - BA/Food Effect Cohort

End point title	Terminal Half-Life (t _{1/2}) - BA/Food Effect Cohort ^[14]
End point description:	
End point type	Primary
End point timeframe:	
Period 1 Day 1, Period 2 Day 1, Period 3 Day 1	

Notes:

[14] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed for this endpoint

End point values	Bioavailability/ Food Effect Cohort - fasting - capsule	Bioavailability/ Food Effect Cohort - fasting - tablet	Bioavailability/ Food Effect Cohort - fed	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	4	4	4	
Units: hr				
arithmetic mean (standard deviation)				
Period 1 Day 1	14.350 (± 8.2051)	9.686 (± 5.2947)	8.793 (± 4.2063)	
Period 2 Day 1	8.569 (± 4.0371)	13.261 (± 5.2962)	11.286 (± 4.9139)	
Period 3 Day 1	13.301 (± 3.4328)	7.856 (± 3.8410)	11.896 (± 99999)	

Statistical analyses

No statistical analyses for this end point

Primary: Apparent Total Body Clearance (CL/F)

End point title	Apparent Total Body Clearance (CL/F) ^{[15][16]}
End point description:	
End point type	Primary
End point timeframe:	
Cycle 1 Day 1	

Notes:

[15] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed for this endpoint

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was not evaluated in all the cohorts

End point values	QD 0.5 mg	QD 1 mg	QD 2 mg	QD 4 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	4
Units: mL/hr				
geometric mean (geometric coefficient of variation)	6565.92 (± 99999)	10744.76 (± 99999)	34811.99 (± 99999)	16884.66 (± 48.4)

End point values	QD 8 mg	QD 16 mg	QD 25 mg	QD 40 mg
------------------	---------	----------	----------	----------

Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	6	6	5
Units: mL/hr				
geometric mean (geometric coefficient of variation)	33687.82 (\pm 64.1)	25605.72 (\pm 81.7)	13073.92 (\pm 92.1)	18782.26 (\pm 45.3)

End point values	BID 10 mg	BID 15 mg	Dose Expansion cohort - HNSCC	Dose Expansion cohort - CRPC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	5	5	6
Units: mL/hr				
geometric mean (geometric coefficient of variation)	33040.44 (\pm 60.7)	22960.71 (\pm 48.4)	45310 (\pm 154.48)	22940 (\pm 53.42)

Statistical analyses

No statistical analyses for this end point

Primary: Apparent Total Body Clearance (CL/F) - BA/Food Effect Cohort

End point title	Apparent Total Body Clearance (CL/F) - BA/Food Effect
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Period 1 Day 1, Period 2 Day 1, Period 3 Day 1

Notes:

[17] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed for this endpoint

End point values	Bioavailability/ Food Effect Cohort - fasting - capsule	Bioavailability/ Food Effect Cohort - fasting - tablet	Bioavailability/ Food Effect Cohort - fed	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	4	4	4	
Units: L/hr				
geometric mean (geometric coefficient of variation)				
Period 1 Day 1	11.49 (\pm 79.06)	19.79 (\pm 155.44)	17.07 (\pm 96.77)	
Period 2 Day 1	16.08 (\pm 115.72)	12.01 (\pm 75.74)	13.89 (\pm 3.87)	
Period 3 Day 1	9.78 (\pm 65.26)	13.79 (\pm 79.47)	14.99 (\pm 99999)	

Statistical analyses

No statistical analyses for this end point

Primary: Apparent Volume of Distribution (V_z/F)

End point title	Apparent Volume of Distribution (V _z /F) ^{[18][19]}
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Day 1

Notes:

[18] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed for this endpoint

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was not evaluated in all the cohorts

End point values	QD 0.5 mg	QD 1 mg	QD 2 mg	QD 4 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	4
Units: mL				
geometric mean (geometric coefficient of variation)	113002.05 (± 99999)	164320.03 (± 99999)	310044.82 (± 99999)	159056.04 (± 33.0)

End point values	QD 8 mg	QD 16 mg	QD 25 mg	QD 40 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	5	6	6	5
Units: mL				
geometric mean (geometric coefficient of variation)	293636.64 (± 57.1)	263877.04 (± 103.5)	149036.99 (± 42.4)	200931.87 (± 28.9)

End point values	BID 10 mg	BID 15 mg	Dose Expansion cohort - HNSCC	Dose Expansion cohort - CRPC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	3	5	5	6
Units: mL				
geometric mean (geometric coefficient of variation)	189478.26 (± 57.1)	172900.26 (± 103.5)	200450 (± 42.4)	136170 (± 28.9)

of variation)	35.9)	36.3)	63.45)	25.44)
---------------	-------	-------	--------	--------

Statistical analyses

No statistical analyses for this end point

Primary: Apparent Volume of Distribution (V_z/F) - BA/Food Effect Cohort

End point title	Apparent Volume of Distribution (V _z /F) - BA/Food Effect
-----------------	--

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Period 1 Day1, Period 2 Day 1, Period 3 Day 1

Notes:

[20] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed for this endpoint

End point values	Bioavailability/ Food Effect Cohort - fasting - capsule	Bioavailability/ Food Effect Cohort - fasting - tablet	Bioavailability/ Food Effect Cohort - fed	
Subject group type	Subject analysis set	Subject analysis set	Subject analysis set	
Number of subjects analysed	4	4	4	
Units: Liters				
geometric mean (geometric coefficient of variation)				
Period 1 Day 1	213.60 (± 179.03)	229.85 (± 42.80)	201.49 (± 58.84)	
Period 2 Day 1	185.77 (± 61.82)	217.90 (± 121.48)	215.12 (± 42.93)	
Period 3 Day 1	183.06 (± 56.26)	145.21 (± 37.93)	257.31 (± 99999)	

Statistical analyses

No statistical analyses for this end point

Primary: Drug Accumulation Ratio (Rac)

End point title	Drug Accumulation Ratio (Rac) ^{[21][22]}
-----------------	---

End point description:

End point type	Primary
----------------	---------

End point timeframe:

Cycle 1 Day 15

Notes:

[21] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: No statistical analyses were performed for this endpoint

[22] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was not evaluated in all the cohorts

End point values	QD 0.5 mg	QD 1 mg	QD 2 mg	QD 4 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	3
Units: Ratio				
arithmetic mean (standard deviation)	1.18 (± 99999)	1.63 (± 99999)	1.12 (± 99999)	1.33 (± 0.250)

End point values	QD 8 mg	QD 16 mg	QD 25 mg	QD 40 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	5	4
Units: Ratio				
arithmetic mean (standard deviation)	1.15 (± 0.183)	1.36 (± 0.280)	1.15 (± 0.075)	2.94 (± 3.485)

End point values	BID 10 mg	BID 15 mg	Dose Expansion cohort - HNSCC	Dose Expansion cohort - CRPC
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	5	4	3
Units: Ratio				
arithmetic mean (standard deviation)	2.35 (± 0.599)	4.33 (± 2.716)	3.115 (± 2.8558)	1.667 (± 0.3008)

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in Blood Levels of Phosphorylated 4E-Binding Protein 1 (pE4-BP1)

End point title	Change from Baseline in Blood Levels of Phosphorylated 4E-Binding Protein 1 (pE4-BP1) ^[23]
-----------------	---

End point description:

Changes in pE4-BP1 (CD91+) are presented here

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline to Cycle 1 Day 2 (pre-dose)

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was not evaluated in all the cohorts

End point values	QD 0.5 mg	QD 1 mg	QD 2 mg	QD 4 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[24]	1	1	4
Units: Percent change from baseline				
arithmetic mean (standard deviation)	()	21.6 (± 99999)	-8.9 (± 99999)	10.7 (± 26.31)

Notes:

[24] - No subjects analyzed in this cohort

End point values	QD 8 mg	QD 16 mg	QD 25 mg	QD 40 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	6	5	4
Units: Percent change from baseline				
arithmetic mean (standard deviation)	-3.4 (± 15.87)	-33.8 (± 21.03)	-14.4 (± 20.43)	6.9 (± 34.94)

End point values	BID 10 mg	BID 15 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[25]	0 ^[26]		
Units: Percent change from baseline				
arithmetic mean (standard deviation)	()	()		

Notes:

[25] - No subjects analyzed in this cohort

[26] - No subjects analyzed in this cohort

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Percent Ratio of Phosphorylated AKT (p-AKT)/ Total AKT

End point title	Change from Baseline in the Percent Ratio of Phosphorylated AKT (p-AKT)/ Total AKT ^[27]
-----------------	--

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

From baseline to Cycle 1 Day 2 (pre-dose)

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was not evaluated in all the cohorts

End point values	QD 0.5 mg	QD 1 mg	QD 2 mg	QD 4 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	0 ^[28]	0 ^[29]	1	4
Units: Percent change from baseline				
arithmetic mean (standard deviation)	()	()	-40.8 (± 99999)	23.7 (± 96.75)

Notes:

[28] - No subjects analyzed in this cohort

[29] - No subjects analyzed in this cohort

End point values	QD 8 mg	QD 16 mg	QD 25 mg	QD 40 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	4	6	6	6
Units: Percent change from baseline				
arithmetic mean (standard deviation)	-47.6 (± 14.18)	7.2 (± 70.69)	-25.8 (± 40.05)	-57.1 (± 27.51)

End point values	BID 10 mg	BID 15 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[30]	0 ^[31]		
Units: Percent change from baseline				
arithmetic mean (standard deviation)	()	()		

Notes:

[30] - No subjects analyzed in this cohort

[31] - No subjects analyzed in this cohort

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in the Levels of UV-Stimulated phosphorylated DNA-dependent Protein Kinase (pDNA-PK)

End point title	Change from Baseline in the Levels of UV-Stimulated phosphorylated DNA-dependent Protein Kinase (pDNA-PK) ^[32]
End point description:	
From baseline to Cycle 1 Day 15	
End point type	Secondary
End point timeframe:	
pDNA-PK measured as H-score	

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: This endpoint was not evaluated in all the cohorts

End point values	QD 0.5 mg	QD 1 mg	QD 2 mg	QD 4 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	3
Units: Percent change from baseline				
arithmetic mean (standard deviation)	-16.7 (± 99999)	14.9 (± 99999)	1.5 (± 99999)	2.2 (± 19.30)

End point values	QD 8 mg	QD 16 mg	QD 25 mg	QD 40 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	5	6	4
Units: Percent change from baseline				
arithmetic mean (standard deviation)	-3.1 (± 12.58)	2.7 (± 21.20)	1.9 (± 24.68)	17.9 (± 24.88)

End point values	BID 10 mg	BID 15 mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	0 ^[33]	0 ^[34]		
Units: Percent change from baseline				
arithmetic mean (standard deviation)	()	()		

Notes:

[33] - No subjects analyzed in this cohort

[34] - No subjects analyzed in this cohort

Statistical analyses

No statistical analyses for this end point

Secondary: Objective Response Rate (ORR)

End point title	Objective Response Rate (ORR)
-----------------	-------------------------------

End point description:

ORR is defined as the percentage of participants achieving a Complete Response (CR) or Partial Response (PR). Results are presented separately for Confirmed and Unconfirmed Responses. Unconfirmed Responses are based on investigator assessment using tumor-appropriate evaluation criteria.

End point type	Secondary
----------------	-----------

End point timeframe:

From first dose to end of study, assessed every 2 cycles for the first 6 cycles, then every 3 cycles through the end of first year on study and then every 6 cycles thereafter

End point values	QD 0.5 mg	QD 1 mg	QD 2 mg	QD 4 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	1	1	1	4
Units: Percent of Participants				
number (confidence interval 95%)				

Unconfirmed responses	0 (-99999 to 99999)	0 (-99999 to 99999)	0 (-99999 to 99999)	0 (-99999 to 99999)
Confirmed responses	0 (-99999 to 99999)	0 (-99999 to 99999)	0 (-99999 to 99999)	0 (-99999 to 99999)

End point values	QD 8 mg	QD 16 mg	QD 25 mg	QD 40 mg
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	7	6
Units: Percent of Participants				
number (confidence interval 95%)				
Unconfirmed responses	0 (-99999 to 99999)	0 (-99999 to 99999)	16.7 (0.4 to 64.1)	0 (-99999 to 99999)
Confirmed responses	0 (-99999 to 99999)	0 (-99999 to 99999)	0 (-99999 to 99999)	0 (-99999 to 99999)

End point values	BID 10 mg	BID 15 mg	Dose Expansion cohort - HNSCC	Dose Expansion cohort - GBM
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	6	6	17	0 ^[35]
Units: Percent of Participants				
number (confidence interval 95%)				
Unconfirmed responses	16.7 (0.4 to 64.1)	0 (-99999 to 99999)	0 (0 to 19.5)	(to)
Confirmed responses	16.7 (0.4 to 64.1)	0 (-99999 to 99999)	0 (0 to 19.5)	(to)

Notes:

[35] - No measurements available for this cohort

End point values	Dose Expansion cohort - CLL/SLL	Dose Expansion cohort - CRPC	Dose Expansion cohort - ES	Dose Expansion cohort - BA/Food Effect
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	8	11	9	11
Units: Percent of Participants				
number (confidence interval 95%)				
Unconfirmed responses	12.5 (0.3 to 52.7)	0 (0 to 28.5)	0 (0 to 33.6)	18.2 (2.3 to 51.8)
Confirmed responses	99999 (99999 to 99999)	99999 (99999 to 99999)	0 (0 to 33.6)	0 (0 to 28.5)

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first dose to 100 days following last dose

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.0
--------------------	------

Reporting groups

Reporting group title	QD 0.5 mg
-----------------------	-----------

Reporting group description:

CC-115 administered once a day at a dose of 0.5 mg

Reporting group title	QD 1 mg
-----------------------	---------

Reporting group description:

CC-115 administered once a day at a dose of 1 mg

Reporting group title	QD 2 mg
-----------------------	---------

Reporting group description:

CC-115 administered once a day at a dose of 2 mg

Reporting group title	QD 4 mg
-----------------------	---------

Reporting group description:

CC-115 administered once a day at a dose of 4 mg

Reporting group title	QD 8 mg
-----------------------	---------

Reporting group description:

CC-115 administered once a day at a dose of 8 mg

Reporting group title	QD 16 mg
-----------------------	----------

Reporting group description:

CC-115 administered once a day at a dose of 16 mg

Reporting group title	QD 25 mg
-----------------------	----------

Reporting group description:

CC-115 administered once a day at a dose of 25 mg

Reporting group title	QD 40 mg
-----------------------	----------

Reporting group description:

CC-115 administered once a day at a dose of 40 mg

Reporting group title	Dose Expansion cohort - HNSCC
-----------------------	-------------------------------

Reporting group description:

Participants diagnosed with Head and Neck Squamous Cell Carcinoma (HNSCC). CC-115 administered twice a day at a dose of 10 mg

Reporting group title	BID 15 mg
-----------------------	-----------

Reporting group description:

CC-115 administered twice a day at a dose of 15 mg

Reporting group title	BID 10 mg
-----------------------	-----------

Reporting group description:

CC-115 administered twice a day at a dose of 10 mg

Reporting group title	Dose Expansion cohort - GBM
-----------------------	-----------------------------

Reporting group description:

Participants diagnosed with Glioblastoma Multiforme (GBM). CC-115 administered twice a day at a dose of 10 mg

Reporting group title	Dose Expansion cohort - ES
-----------------------	----------------------------

Reporting group description:

Participants diagnosed with Ewing's sarcoma (ES). CC-115 administered twice a day at a dose of 10 mg

Reporting group title	Dose Expansion cohort - CRPC
Reporting group description: Participants diagnosed with Castration-Resistant Prostate Cancer (CRPC). CC-115 administered twice a day at a dose of 10 mg	
Reporting group title	Dose Expansion cohort - CLL/SLL
Reporting group description: Participants diagnosed with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). CC-115 administered twice a day at a dose of 10 mg	
Reporting group title	Dose Expansion cohort - BA/Food Effect
Reporting group description: Participants diagnosed with any tumor type and who were treated in the bioavailability(BA)/food effect substudy. CC-115 administered under fasted or fed conditions at 10 mg dose	

Serious adverse events	QD 0.5 mg	QD 1 mg	QD 2 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma gastric			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alveolar soft part sarcoma metastatic			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cancer pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangiocarcinoma			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ewing's sarcoma metastatic			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leiomyosarcoma			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Richter's syndrome			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovial sarcoma			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Fatigue			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General physical health deterioration			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Hypoxia	subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pleural effusion	subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis	subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism	subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary venous thrombosis	subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure	subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders				
Homicidal ideation				
	subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations				
Aspartate aminotransferase increased				
	subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
	occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
	deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Femoral neck fracture			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle strain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Aortic valve disease			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall haematoma			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric perforation			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct obstruction			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue			

disorders			
Back pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Flank pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Meningitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypercalcaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	QD 4 mg	QD 8 mg	QD 16 mg
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 4 (75.00%)	2 / 6 (33.33%)	3 / 6 (50.00%)
number of deaths (all causes)	2	0	1
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma gastric			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Alveolar soft part sarcoma metastatic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Cancer pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangiocarcinoma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ewing's sarcoma metastatic			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Leiomyosarcoma			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Richter's syndrome			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovial sarcoma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General physical health deterioration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pleural effusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary venous thrombosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Homicidal ideation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Injury, poisoning and procedural complications			
Femoral neck fracture			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle strain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Aortic valve disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall haematoma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric perforation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct obstruction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Flank pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypercalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	QD 25 mg	QD 40 mg	Dose Expansion cohort - HNSCC
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 7 (28.57%)	2 / 6 (33.33%)	8 / 18 (44.44%)
number of deaths (all causes)	1	1	3
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma gastric			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alveolar soft part sarcoma metastatic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cancer pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangiocarcinoma			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 1	0 / 0
Ewing's sarcoma metastatic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leiomyosarcoma			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Richter's syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovial sarcoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General physical health deterioration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Non-cardiac chest pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pleural effusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary venous thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Homicidal ideation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Injury, poisoning and procedural complications			
Femoral neck fracture			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle strain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Aortic valve disease			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall haematoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric perforation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct obstruction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Flank pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	2 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Septic shock			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypercalcaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	BID 15 mg	BID 10 mg	Dose Expansion cohort - GBM
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 6 (33.33%)	3 / 6 (50.00%)	5 / 14 (35.71%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma gastric			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alveolar soft part sarcoma metastatic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cancer pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangiocarcinoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ewing's sarcoma metastatic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leiomyosarcoma			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Richter's syndrome			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovial sarcoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General physical health deterioration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Non-cardiac chest pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	2 / 6 (33.33%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pleural effusion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary venous thrombosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Homicidal ideation			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Injury, poisoning and procedural complications			
Femoral neck fracture			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle strain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Aortic valve disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall haematoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric perforation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bile duct obstruction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Flank pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypercalcaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Dose Expansion cohort - ES	Dose Expansion cohort - CRPC	Dose Expansion cohort - CLL/SLL
Total subjects affected by serious adverse events			
subjects affected / exposed	4 / 10 (40.00%)	4 / 12 (33.33%)	5 / 8 (62.50%)
number of deaths (all causes)	2	0	2
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma gastric			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Alveolar soft part sarcoma metastatic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cancer pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cholangiocarcinoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ewing's sarcoma metastatic			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Leiomyosarcoma			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Richter's syndrome			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Synovial sarcoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Tumour pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypotension			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Fatigue			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

General physical health deterioration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Non-cardiac chest pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyrexia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Dyspnoea			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hypoxia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Pleural effusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	1 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary embolism			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pulmonary venous thrombosis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory failure			
subjects affected / exposed	2 / 10 (20.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 2	0 / 0	0 / 0
Psychiatric disorders			
Homicidal ideation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Injury, poisoning and procedural complications			
Femoral neck fracture			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Muscle strain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Subdural haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wound dehiscence			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
Aortic valve disease			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Seizure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Thrombocytopenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Abdominal wall haematoma			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Constipation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastric perforation			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nausea			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pancreatitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Small intestinal obstruction			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Vomiting			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 1
Bile duct obstruction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatic failure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hydronephrosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Flank pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Bacteraemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Device related infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Escherichia bacteraemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Meningitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pyelonephritis acute			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Sepsis			
subjects affected / exposed	1 / 10 (10.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Septic shock			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Urinary tract infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	1 / 8 (12.50%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Metabolism and nutrition disorders			
Hypercalcaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyperglycaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hyponatraemia			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Dose Expansion cohort - BA/Food Effect		
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 12 (58.33%)		
number of deaths (all causes)	4		
number of deaths resulting from adverse events			
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Adenocarcinoma gastric			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Alveolar soft part sarcoma metastatic			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cancer pain			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Cholangiocarcinoma			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Ewing's sarcoma metastatic			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Leiomyosarcoma			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Richter's syndrome			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Synovial sarcoma			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 1		
Tumour pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hypotension			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Fatigue			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		

General physical health deterioration				
subjects affected / exposed	2 / 12 (16.67%)			
occurrences causally related to treatment / all	0 / 2			
deaths causally related to treatment / all	0 / 2			
Non-cardiac chest pain				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pain				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Pyrexia				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Respiratory, thoracic and mediastinal disorders				
Acute respiratory failure				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Chronic obstructive pulmonary disease				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Dyspnoea				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			
Hypoxia				
subjects affected / exposed	0 / 12 (0.00%)			
occurrences causally related to treatment / all	0 / 0			
deaths causally related to treatment / all	0 / 0			

Pleural effusion			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary embolism			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pulmonary venous thrombosis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Respiratory failure			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Psychiatric disorders			
Homicidal ideation			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Investigations			
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Injury, poisoning and procedural complications			
Femoral neck fracture			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Muscle strain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Subdural haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Wound dehiscence			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Cardiac disorders			
Aortic valve disease			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nervous system disorders			
Headache			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Seizure			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Blood and lymphatic system disorders			
Anaemia			

subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Thrombocytopenia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Abdominal wall haematoma			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Constipation			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Gastric perforation			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Nausea			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pancreatitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Small intestinal obstruction			

subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Vomiting			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatobiliary disorders			
Acute hepatic failure			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bile duct obstruction			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hepatic failure			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hydronephrosis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal and connective tissue disorders			
Back pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Flank pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Musculoskeletal pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infections and infestations			
Acute sinusitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Bacteraemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Device related infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Escherichia bacteraemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Infection			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	0 / 1		
deaths causally related to treatment / all	0 / 0		
Meningitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pneumonia			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Pyelonephritis acute			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Sepsis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Septic shock			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 1		
Urinary tract infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Metabolism and nutrition disorders			
Hypercalcaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyperglycaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		
Hyponatraemia			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences causally related to treatment / all	0 / 0		
deaths causally related to treatment / all	0 / 0		

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	QD 0.5 mg	QD 1 mg	QD 2 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	1 / 1 (100.00%)	1 / 1 (100.00%)	1 / 1 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Melanocytic naevus			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Tumour haemorrhage			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Tumour necrosis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Arterial disorder			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Deep vein thrombosis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Flushing			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Haematoma			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Hypotension			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Orthostatic hypotension			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pallor			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Peripheral coldness			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Chest discomfort			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	3	0
Cyst			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Discomfort			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Early satiety			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	5	0
Gait disturbance			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
General physical health deterioration			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Pain			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	6	0
Swelling			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Temperature intolerance			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Tenderness			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Social circumstances			
HEARING IMPAIRMENT			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Cervical polyp			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Gynaecomastia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Penile pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Vaginal discharge			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal swelling			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
DYSPNEA ON EXERTION			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Atelectasis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Bronchial obstruction			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Bronchospasm			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Catarrh			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 1 (100.00%)
occurrences (all)	0	0	1
Dysphonia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			

subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	2	0
Dyspnoea at rest			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Increased bronchial secretion			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Lung infiltration			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Nasal inflammation			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Paranasal sinus discomfort			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pharyngeal inflammation			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pleuritic pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pneumothorax			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pulmonary oedema			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Respiratory tract congestion			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Sputum discoloured			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Abulia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Agitation			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Bradyphrenia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Irritability			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Nervousness			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Personality change			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Restlessness			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Sleep disorder			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Investigations			
Activated partial thromboplastin time prolonged			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Amylase increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Bacterial test positive			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blood albumin decreased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Blood cholesterol increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blood insulin increased			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blood phosphorus increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 1 (100.00%)
occurrences (all)	0	0	1
Blood triglycerides increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Breath sounds abnormal			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
CD4 lymphocytes increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Eosinophil count increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Glucose urine present			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Glycosylated haemoglobin increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	1 / 1 (100.00%)
occurrences (all)	0	0	1
Insulin C-peptide increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Tandem gait test abnormal			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Thyroxine increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Transaminases increased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Weight increased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Injury, poisoning and procedural complications			
Arthropod bite subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Ear injury subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Foreign body in eye subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Head injury subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Inappropriate schedule of product administration subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Injury corneal subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Muscle strain subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Overdose			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Post procedural discomfort			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin wound			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
Primary immunodeficiency syndrome			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Cardiomyopathy			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Supraventricular tachycardia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Tachycardia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
MITRAL VALVE DISEASE			

subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Apraxia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Ataxia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Disturbance in attention			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	2	0
Dysaesthesia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dysarthria			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Facial neuralgia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Facial paralysis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Formication			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Headache			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Hemiparesis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hyperaesthesia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypersomnia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Neurotoxicity			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Seizure			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Sensory disturbance			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Sensory loss			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Taste disorder			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Trigeminal nerve paresis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Vocal cord paralysis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Eosinophilia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Leukocytosis			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Normocytic anaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Deafness bilateral			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Ear discomfort			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Ear pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Eustachian tube disorder			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Vertigo positional			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blindness unilateral			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Chorioretinal disorder			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Eye disorder			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Eye pruritus			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Eyelid ptosis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Scleral hyperaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Strabismus			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Vision blurred			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Abdominal pain upper			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Abdominal tenderness			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	2	0
Anal incontinence			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Anal inflammation			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Anorectal discomfort			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Breath odour			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Colitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dental caries			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Dry mouth			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Dyspepsia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Frequent bowel movements			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Glossodynia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Odynophagia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Rectal discharge			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Toothache			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Vomiting			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hepatobiliary disorders			
Bile duct stenosis			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Biliary dilatation			

subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Jaundice			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Jaundice cholestatic			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
PRURITIC LESIONS			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Acne			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Blister			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dermal cyst			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0

Eczema			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Erythema nodosum			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Ingrowing nail			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Intertrigo			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Nail disorder			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Nodular rash			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Onychalgia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pain of skin			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0

Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Photosensitivity reaction			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Pruritus generalised			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Purpura			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Rash erythematous			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Rash generalised			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	2	0
Rash papular			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Scab			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Skin discolouration			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin irritation			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin mass			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin ulcer haemorrhage			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Toxic skin eruption			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Dysuria			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Glycosuria			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Incontinence			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Leukocyturia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Renal atrophy			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Renal vein thrombosis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Urinary hesitation			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Urinary retention subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Bone pain subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Coccydynia subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Flank pain subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Groin pain subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Intervertebral disc protrusion subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	1 / 1 (100.00%) 1	0 / 1 (0.00%) 0
Joint stiffness subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Joint swelling subjects affected / exposed occurrences (all)	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0	0 / 1 (0.00%) 0
Muscle spasms			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Muscle twitching			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal discomfort			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Musculoskeletal pain			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Pain in extremity			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Pain in jaw			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Spondylitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Temporomandibular joint syndrome			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Trismus			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Cellulitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Eye infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Fungal skin infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0

Kidney infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Laryngitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Lung infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Mastoiditis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Nasal vestibulitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Onychomycosis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Otitis externa			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Pneumonia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Postoperative wound infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Sepsis			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Staphylococcal infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Viral infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Wound infection			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Dehydration			
subjects affected / exposed	1 / 1 (100.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	1	0	0
Failure to thrive			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	0 / 1 (0.00%)	1 / 1 (100.00%)	0 / 1 (0.00%)
occurrences (all)	0	1	0
Hyperkalaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypervolaemia			

subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Increased appetite			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 1 (0.00%)	0 / 1 (0.00%)	0 / 1 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	QD 4 mg	QD 8 mg	QD 16 mg
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 4 (75.00%)	6 / 6 (100.00%)	6 / 6 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Melanocytic naevus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tumour haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tumour necrosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Arterial disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Deep vein thrombosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Flushing			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haematoma			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Hypertension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Orthostatic hypotension subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Pallor subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Peripheral coldness subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
General disorders and administration site conditions			
Asthenia subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Chest discomfort subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Chills subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	2 / 6 (33.33%) 2
Cyst subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Discomfort subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Early satiety subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Face oedema subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Facial pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Fatigue			

subjects affected / exposed	1 / 4 (25.00%)	1 / 6 (16.67%)	2 / 6 (33.33%)
occurrences (all)	2	1	3
Gait disturbance			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
General physical health deterioration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Non-cardiac chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Oedema peripheral			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
Pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Peripheral swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	1 / 4 (25.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)
occurrences (all)	1	1	1
Swelling			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Temperature intolerance			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tenderness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Social circumstances			
HEARING IMPAIRMENT			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			
Cervical polyp			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gynaecomastia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Penile pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vaginal discharge			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
DYSPNEA ON EXERTION			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Atelectasis			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Bronchial obstruction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Bronchospasm			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Catarrh			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Dysphonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	2 / 4 (50.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	2	0	2
Dyspnoea at rest			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Epistaxis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Hiccups			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Increased bronchial secretion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lung infiltration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Nasal inflammation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Paranasal sinus discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pharyngeal inflammation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pleuritic pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pneumothorax			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	3 / 6 (50.00%)
occurrences (all)	0	0	4

Pulmonary embolism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pulmonary oedema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory tract congestion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sputum discoloured			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Abulia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Agitation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Bradyphrenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Depression			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Irritability			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nervousness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Personality change			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Restlessness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sleep disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Alanine aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Amylase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Bacterial test positive			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood albumin decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood bilirubin increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood cholesterol increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Blood insulin increased			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	2 / 6 (33.33%)
occurrences (all)	1	0	2
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Blood phosphorus increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone increased			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Breath sounds abnormal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
CD4 lymphocytes increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eosinophil count increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Glucose urine present			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Glycosylated haemoglobin increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Insulin C-peptide increased			
subjects affected / exposed	1 / 4 (25.00%)	1 / 6 (16.67%)	3 / 6 (50.00%)
occurrences (all)	1	1	4
International normalised ratio increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lipase increased			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tandem gait test abnormal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Thyroxine increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Transaminases increased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	3
Weight increased			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
White blood cell count decreased			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
Arthropod bite			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Contusion			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Ear injury			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Foreign body in eye			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Head injury			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Inappropriate schedule of product administration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Injury corneal			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Overdose			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Post procedural discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Skin wound subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Congenital, familial and genetic disorders Primary immunodeficiency syndrome subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Cardiac disorders Angina pectoris subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Cardiomyopathy subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Palpitations subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Supraventricular tachycardia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
MITRAL VALVE DISEASE subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Nervous system disorders Aphasia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Apraxia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Ataxia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0

Disturbance in attention subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Dizziness subjects affected / exposed occurrences (all)	1 / 4 (25.00%) 1	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Dysaesthesia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Dysarthria subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Dysgeusia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1
Facial neuralgia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Facial paralysis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1
Formication subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Headache subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	2 / 6 (33.33%) 3
Hemiparesis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Hyperaesthesia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Hypersomnia subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0

Hypoaesthesia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lethargy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Memory impairment			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neurotoxicity			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Seizure			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Sensory disturbance			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Sensory loss			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Somnolence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Taste disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Trigeminal nerve paresis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vocal cord paralysis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	3	0	1
Eosinophilia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Leukocytosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Normocytic anaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			

subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	1 / 6 (16.67%) 3
Ear and labyrinth disorders			
Deafness bilateral subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Ear discomfort subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Ear pain subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Eustachian tube disorder subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Hypoacusis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Tinnitus subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Vertigo positional subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Eye disorders			
Blepharitis subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Blindness unilateral subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Cataract subjects affected / exposed occurrences (all)	0 / 4 (0.00%) 0	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0
Chorioretinal disorder			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye pruritus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eyelid ptosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Scleral hyperaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Strabismus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Abdominal distension			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1

Abdominal pain			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	2 / 6 (33.33%)
occurrences (all)	1	0	3
Abdominal pain lower			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 4 (0.00%)	2 / 6 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Abdominal tenderness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Anal incontinence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Anal inflammation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Anorectal discomfort			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Breath odour			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Colitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	0 / 4 (0.00%)	2 / 6 (33.33%)	2 / 6 (33.33%)
occurrences (all)	0	2	2
Dental caries			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Diarrhoea			
subjects affected / exposed	0 / 4 (0.00%)	2 / 6 (33.33%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Dry mouth			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	1 / 6 (16.67%)
occurrences (all)	0	1	1
Dyspepsia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dysphagia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Frequent bowel movements			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Glossodynia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	0 / 4 (0.00%)	4 / 6 (66.67%)	3 / 6 (50.00%)
occurrences (all)	0	5	4
Odynophagia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Oral pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rectal discharge			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Toothache			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	2 / 4 (50.00%)	2 / 6 (33.33%)	2 / 6 (33.33%)
occurrences (all)	3	4	4
Hepatobiliary disorders			
Bile duct stenosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Biliary dilatation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Jaundice			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Jaundice cholestatic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			

PRURITIC LESIONS			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Acne			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Alopecia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Blister			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermal cyst			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Erythema			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Erythema nodosum			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Ingrowing nail			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Intertrigo			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nail disorder			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Nodular rash			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Onychalgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pain of skin			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Photosensitivity reaction			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Pruritus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Pruritus generalised			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Purpura			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Rash erythematous			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash generalised			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Rash papular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Scab			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin discolouration			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Skin fissures			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin irritation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Skin mass			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin ulcer haemorrhage			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Toxic skin eruption			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Glycosuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Incontinence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Leukocyturia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Renal atrophy			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Renal vein thrombosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urinary hesitation			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urinary retention			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Back pain			

subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Bone pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Coccydynia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Joint stiffness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	1 / 4 (25.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	3	1	0
Muscle twitching			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Musculoskeletal discomfort			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	2	0
Myalgia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Pain in jaw			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Spondylitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Temporomandibular joint syndrome			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Trismus			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Cellulitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Eye infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Fungal skin infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Kidney infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Laryngitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Lung infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Mastoiditis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Nasal vestibulitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Onychomycosis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Otitis externa			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Postoperative wound infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Sepsis			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Staphylococcal infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	1
Urinary tract infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection bacterial			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Wound infection			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			

subjects affected / exposed	0 / 4 (0.00%)	2 / 6 (33.33%)	1 / 6 (16.67%)
occurrences (all)	0	2	2
Dehydration			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	1	0	0
Failure to thrive			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	1 / 4 (25.00%)	0 / 6 (0.00%)	3 / 6 (50.00%)
occurrences (all)	2	0	3
Hyperkalaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypertriglyceridaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hyperuricaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypervolaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	1 / 6 (16.67%)
occurrences (all)	0	0	2
Hypocalcaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			

subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 4 (0.00%)	1 / 6 (16.67%)	0 / 6 (0.00%)
occurrences (all)	0	1	0
Hyponatraemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	2 / 6 (33.33%)
occurrences (all)	0	0	2
Hypophosphataemia			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Increased appetite			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 4 (0.00%)	0 / 6 (0.00%)	0 / 6 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	QD 25 mg	QD 40 mg	Dose Expansion cohort - HNSCC
Total subjects affected by non-serious adverse events			
subjects affected / exposed	7 / 7 (100.00%)	6 / 6 (100.00%)	18 / 18 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Melanocytic naevus			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Tumour haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Tumour necrosis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Tumour pain			

subjects affected / exposed occurrences (all)	0 / 7 (0.00%) 0	0 / 6 (0.00%) 0	2 / 18 (11.11%) 1
Vascular disorders			
Arterial disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Deep vein thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	2 / 18 (11.11%)
occurrences (all)	0	1	2
Flushing			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Haematoma			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	0
Hypotension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Orthostatic hypotension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pallor			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Peripheral coldness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			

Asthenia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	3 / 18 (16.67%)
occurrences (all)	0	1	9
Chest discomfort			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Chills			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	2
Cyst			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Discomfort			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Early satiety			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Facial pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	6 / 7 (85.71%)	5 / 6 (83.33%)	11 / 18 (61.11%)
occurrences (all)	9	9	18
Gait disturbance			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
General physical health deterioration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0

Malaise			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Mucosal inflammation			
subjects affected / exposed	1 / 7 (14.29%)	2 / 6 (33.33%)	3 / 18 (16.67%)
occurrences (all)	1	2	6
Non-cardiac chest pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	2 / 7 (28.57%)	1 / 6 (16.67%)	2 / 18 (11.11%)
occurrences (all)	2	1	4
Pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Peripheral swelling			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	5 / 18 (27.78%)
occurrences (all)	1	0	5
Swelling			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Temperature intolerance			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Tenderness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Social circumstances			
HEARING IMPAIRMENT			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Reproductive system and breast disorders			

Cervical polyp			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Gynaecomastia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Penile pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Vaginal discharge			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Vulvovaginal swelling			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
DYSPNEA ON EXERTION			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Atelectasis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Bronchial obstruction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Bronchospasm			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Catarrh			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	2 / 18 (11.11%)
occurrences (all)	0	1	2
Dysphonia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	2
Dyspnoea			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	6
Dyspnoea at rest			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Dyspnoea exertional			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Epistaxis			
subjects affected / exposed	2 / 7 (28.57%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	2	0	0
Haemoptysis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Increased bronchial secretion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1

Lung infiltration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nasal inflammation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Paranasal sinus discomfort			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pharyngeal inflammation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pleuritic pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pneumothorax			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Productive cough			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pulmonary embolism			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pulmonary oedema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Respiratory tract congestion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0

Rhinorrhoea			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Sputum discoloured			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Wheezing			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Abulia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Agitation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Bradyphrenia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 7 (0.00%)	2 / 6 (33.33%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Depression			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Insomnia			
subjects affected / exposed	1 / 7 (14.29%)	1 / 6 (16.67%)	1 / 18 (5.56%)
occurrences (all)	1	1	1
Irritability			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nervousness			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Personality change			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Restlessness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Sleep disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	2
Alanine aminotransferase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Amylase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Aspartate aminotransferase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Bacterial test positive			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood albumin decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Blood bilirubin increased			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood cholesterol increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood creatinine increased			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	2	0	1
Blood insulin increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	3
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood phosphorus increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Breath sounds abnormal			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
CD4 lymphocytes increased			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Eosinophil count increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Glucose urine present			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Glycosylated haemoglobin increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Insulin C-peptide increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	2
International normalised ratio increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	3
Lipase increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Lymphocyte count decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			

subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Tandem gait test abnormal			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Thyroxine increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Transaminases increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Weight decreased			
subjects affected / exposed	1 / 7 (14.29%)	1 / 6 (16.67%)	7 / 18 (38.89%)
occurrences (all)	1	1	9
Weight increased			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	2	0	0
Injury, poisoning and procedural complications			
Arthropod bite			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Ear injury			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Fall			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Foreign body in eye			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Head injury			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Inappropriate schedule of product administration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Injury corneal			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Overdose			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Post procedural discomfort			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Procedural pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin laceration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin wound			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Congenital, familial and genetic disorders			
Primary immunodeficiency syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			

Angina pectoris			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Cardiomyopathy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Palpitations			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Supraventricular tachycardia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Tachycardia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
MITRAL VALVE DISEASE			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Apraxia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Ataxia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Disturbance in attention			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	1 / 7 (14.29%)	1 / 6 (16.67%)	2 / 18 (11.11%)
occurrences (all)	1	1	2
Dysaesthesia			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dysarthria			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Dysgeusia			
subjects affected / exposed	1 / 7 (14.29%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	1	1	0
Facial neuralgia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Facial paralysis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Formication			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Headache			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	0
Hemiparesis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hyperaesthesia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypersomnia			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Hypoaesthesia			
subjects affected / exposed	1 / 7 (14.29%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	1	2	0
Lethargy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Memory impairment			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Neuralgia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Neurotoxicity			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Paraesthesia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Seizure			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Sensory disturbance			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Sensory loss			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Taste disorder			
subjects affected / exposed	2 / 7 (28.57%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	2	1	0
Tremor			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Trigeminal nerve paresis			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Vocal cord paralysis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	5 / 18 (27.78%)
occurrences (all)	0	0	9
Eosinophilia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Leukocytosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Lymphopenia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Normocytic anaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Ear and labyrinth disorders			
Deafness bilateral			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Ear discomfort			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Ear pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Eustachian tube disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Vertigo positional			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blindness unilateral			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Cataract			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Chorioretinal disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0

Eye disorder			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Eye pruritus			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Eyelid ptosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Scleral hyperaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Strabismus			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Visual impairment			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Abdominal distension			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	2 / 7 (28.57%)	0 / 6 (0.00%)	2 / 18 (11.11%)
occurrences (all)	2	0	2
Abdominal pain lower			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			

subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Abdominal tenderness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Anal incontinence			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Anal inflammation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Anorectal discomfort			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Aphthous ulcer			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Breath odour			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Colitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	2 / 7 (28.57%)	1 / 6 (16.67%)	3 / 18 (16.67%)
occurrences (all)	2	1	3
Dental caries			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	2 / 7 (28.57%)	0 / 6 (0.00%)	4 / 18 (22.22%)
occurrences (all)	4	0	5
Dry mouth			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			

subjects affected / exposed	3 / 7 (42.86%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	3	0	0
Dysphagia			
subjects affected / exposed	0 / 7 (0.00%)	2 / 6 (33.33%)	1 / 18 (5.56%)
occurrences (all)	0	2	2
Flatulence			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Frequent bowel movements			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Gingival bleeding			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Glossodynia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Haemorrhoids			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	4 / 7 (57.14%)	4 / 6 (66.67%)	7 / 18 (38.89%)
occurrences (all)	7	9	7
Odynophagia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	4	0	0
Rectal discharge			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Rectal haemorrhage			

subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Stomatitis			
subjects affected / exposed	3 / 7 (42.86%)	3 / 6 (50.00%)	1 / 18 (5.56%)
occurrences (all)	8	5	2
Toothache			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	5 / 7 (71.43%)	6 / 6 (100.00%)	1 / 18 (5.56%)
occurrences (all)	9	9	1
Hepatobiliary disorders			
Bile duct stenosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Biliary dilatation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Jaundice			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Jaundice cholestatic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
PRURITIC LESIONS			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Acne			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Alopecia			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Blister			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Dermal cyst			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dry skin			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	2
Eczema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Erythema nodosum			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hyperhidrosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Ingrowing nail			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Intertrigo			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nail disorder			

subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Night sweats			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nodular rash			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Onychalgia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pain of skin			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Photosensitivity reaction			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Pruritus generalised			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	6	0	0
Purpura			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0

Rash			
subjects affected / exposed	4 / 7 (57.14%)	2 / 6 (33.33%)	2 / 18 (11.11%)
occurrences (all)	8	2	2
Rash erythematous			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Rash generalised			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	2	0	0
Rash macular			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			
subjects affected / exposed	1 / 7 (14.29%)	1 / 6 (16.67%)	2 / 18 (11.11%)
occurrences (all)	4	1	7
Rash papular			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Scab			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin discolouration			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin irritation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0

Skin mass			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin ulcer haemorrhage			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	0
Toxic skin eruption			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Glycosuria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Incontinence			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Leukocyturia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Proteinuria			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Renal atrophy			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Renal vein thrombosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Urinary hesitation			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Urinary retention			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	2 / 7 (28.57%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	5	0	1
Back pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Bone pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Coccydynia			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Groin pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Joint stiffness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Joint swelling			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Muscle twitching			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Muscular weakness			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Musculoskeletal discomfort			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Myalgia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Neck pain			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	2 / 7 (28.57%)	1 / 6 (16.67%)	0 / 18 (0.00%)
occurrences (all)	2	2	0
Pain in jaw			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Spondylitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Temporomandibular joint syndrome			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Trismus			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Bronchitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0

Cystitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Eye infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Fungal skin infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Herpes zoster			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Kidney infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Laryngitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Lung infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Mastoiditis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Nasal vestibulitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0

Onychomycosis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Oral candidiasis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	3
Oral herpes			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Otitis externa			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Paronychia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pneumonia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Postoperative wound infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Rash pustular			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Sepsis			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0

Staphylococcal infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Tooth infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	2 / 18 (11.11%)
occurrences (all)	1	0	3
Urinary tract infection bacterial			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Viral infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Wound infection			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	5 / 7 (71.43%)	4 / 6 (66.67%)	8 / 18 (44.44%)
occurrences (all)	5	3	9
Dehydration			
subjects affected / exposed	0 / 7 (0.00%)	1 / 6 (16.67%)	2 / 18 (11.11%)
occurrences (all)	0	1	2
Failure to thrive			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypercholesterolaemia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Hyperglycaemia			
subjects affected / exposed	2 / 7 (28.57%)	1 / 6 (16.67%)	4 / 18 (22.22%)
occurrences (all)	2	1	4
Hyperkalaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypertriglyceridaemia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	2 / 18 (11.11%)
occurrences (all)	2	0	2
Hyperuricaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Hypervolaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	1
Hypocalcaemia			
subjects affected / exposed	1 / 7 (14.29%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Hypoglycaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Hypomagnesaemia			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Hyponatraemia			

subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	4 / 18 (22.22%)
occurrences (all)	0	0	3
Hypophosphataemia			
subjects affected / exposed	2 / 7 (28.57%)	1 / 6 (16.67%)	1 / 18 (5.56%)
occurrences (all)	2	1	0
Increased appetite			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 7 (0.00%)	0 / 6 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	BID 15 mg	BID 10 mg	Dose Expansion cohort - GBM
Total subjects affected by non-serious adverse events			
subjects affected / exposed	6 / 6 (100.00%)	6 / 6 (100.00%)	14 / 14 (100.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Melanocytic naevus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Tumour haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Tumour necrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Arterial disorder			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Deep vein thrombosis			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	1
Flushing			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Haematoma			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hot flush			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Hypotension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Orthostatic hypotension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pallor			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Peripheral coldness			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 14 (7.14%)
occurrences (all)	0	1	2
Chest discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Chills			

subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 14 (7.14%)
occurrences (all)	0	2	1
Cyst			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Early satiety			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Facial pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Fatigue			
subjects affected / exposed	4 / 6 (66.67%)	3 / 6 (50.00%)	10 / 14 (71.43%)
occurrences (all)	5	3	12
Gait disturbance			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	2
General physical health deterioration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Non-cardiac chest pain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Oedema peripheral			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 14 (7.14%)
occurrences (all)	0	3	1
Pain			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Peripheral swelling			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pyrexia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	2 / 14 (14.29%)
occurrences (all)	0	5	2
Swelling			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Temperature intolerance			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Tenderness			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Social circumstances			
HEARING IMPAIRMENT			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Reproductive system and breast disorders			
Cervical polyp			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Gynaecomastia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pelvic pain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Penile pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Vaginal discharge			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Vaginal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Vulvovaginal swelling			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
DYSPNEA ON EXERTION			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Atelectasis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Bronchial obstruction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Bronchospasm			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Catarrh			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Cough			

subjects affected / exposed	2 / 6 (33.33%)	2 / 6 (33.33%)	0 / 14 (0.00%)
occurrences (all)	3	2	0
Dysphonia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	3 / 6 (50.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	6	1	0
Dyspnoea at rest			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Epistaxis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	1	0	0
Haemoptysis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hiccups			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Increased bronchial secretion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Lung infiltration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Nasal congestion			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Nasal inflammation			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Paranasal sinus discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pharyngeal inflammation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pleuritic pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pneumothorax			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pulmonary embolism			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pulmonary oedema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Respiratory tract congestion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rhinorrhoea			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Sputum discoloured			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Wheezing			

subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Psychiatric disorders			
Abulia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Agitation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Anxiety			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	2
Bradyphrenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Confusional state			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	3 / 14 (21.43%)
occurrences (all)	0	2	3
Depression			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	2 / 14 (14.29%)
occurrences (all)	0	1	2
Insomnia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	3
Irritability			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Nervousness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Personality change			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Restlessness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1

Sleep disorder subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Investigations			
Activated partial thromboplastin time prolonged subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Alanine aminotransferase increased subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2	1 / 6 (16.67%) 1	1 / 14 (7.14%) 2
Amylase increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	1 / 14 (7.14%) 2
Aspartate aminotransferase increased subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2	0 / 6 (0.00%) 0	1 / 14 (7.14%) 1
Bacterial test positive subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Blood albumin decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Blood alkaline phosphatase increased subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Blood bilirubin increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Blood cholesterol increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 14 (7.14%) 1
Blood creatine phosphokinase increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Blood creatinine increased			

subjects affected / exposed	2 / 6 (33.33%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	7	0	0
Blood insulin increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Blood phosphorus increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Breath sounds abnormal			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
CD4 lymphocytes increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Eosinophil count increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Gamma-glutamyltransferase increased			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	3
Glucose urine present			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Glycosylated haemoglobin increased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	4	0	0
Insulin C-peptide increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 14 (7.14%)
occurrences (all)	0	2	1
Lymphocyte count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	2
Neutrophil count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Platelet count decreased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Tandem gait test abnormal			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Thyroxine increased			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Transaminases increased			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0

Weight decreased subjects affected / exposed occurrences (all)	3 / 6 (50.00%) 4	1 / 6 (16.67%) 1	1 / 14 (7.14%) 1
Weight increased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
White blood cell count decreased subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 14 (7.14%) 1
Injury, poisoning and procedural complications			
Arthropod bite subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	0 / 14 (0.00%) 0
Contusion subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Ear injury subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Fall subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 14 (7.14%) 1
Foreign body in eye subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Head injury subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Inappropriate schedule of product administration subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Injury corneal subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 14 (7.14%) 1
Muscle strain			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Overdose			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Post procedural discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	2
Skin laceration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin wound			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Congenital, familial and genetic disorders			
Primary immunodeficiency syndrome			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Cardiac disorders			
Angina pectoris			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Cardiomyopathy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Palpitations			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Supraventricular tachycardia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Tachycardia			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
MITRAL VALVE DISEASE			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Apraxia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	0
Ataxia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Disturbance in attention			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Dizziness			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	2 / 14 (14.29%)
occurrences (all)	0	1	2
Dysaesthesia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Dysarthria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	2
Facial neuralgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	2
Facial paralysis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0

Formication			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	2 / 14 (14.29%)
occurrences (all)	1	4	2
Hemiparesis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	1
Hyperaesthesia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypersomnia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	1 / 14 (7.14%)
occurrences (all)	0	1	1
Lethargy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	2 / 14 (14.29%)
occurrences (all)	0	1	2
Neuralgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Neuropathy peripheral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Neurotoxicity			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1

Seizure			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	2
Sensory disturbance			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Sensory loss			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	2
Syncope			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Taste disorder			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Tremor			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Trigeminal nerve paresis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Vocal cord paralysis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	1
Eosinophilia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			

subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Leukocytosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Normocytic anaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Thrombocytopenia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Ear and labyrinth disorders			
Deafness bilateral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Ear discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Ear pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Eustachian tube disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypoacusis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Tinnitus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0

Vertigo positional subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Eye disorders			
Blepharitis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Blindness unilateral subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Cataract subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Chorioretinal disorder subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Diplopia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Dry eye subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Eye disorder subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 14 (7.14%) 1
Eye pruritus subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Eyelid ptosis subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 14 (7.14%) 2
Scleral hyperaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 14 (7.14%) 1
Strabismus			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Visual impairment			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	2
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Abdominal distension			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	1 / 6 (16.67%)	2 / 6 (33.33%)	1 / 14 (7.14%)
occurrences (all)	1	3	1
Abdominal pain lower			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Abdominal tenderness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Anal incontinence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Anal inflammation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Anorectal discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0

Aphthous ulcer			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Breath odour			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Colitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Constipation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	2 / 14 (14.29%)
occurrences (all)	0	0	2
Dental caries			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Diarrhoea			
subjects affected / exposed	3 / 6 (50.00%)	3 / 6 (50.00%)	5 / 14 (35.71%)
occurrences (all)	6	10	9
Dry mouth			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	2 / 14 (14.29%)
occurrences (all)	1	0	2
Dyspepsia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Dysphagia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Flatulence			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Frequent bowel movements			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0

Gingival bleeding			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Glossodynia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Haemorrhoids			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Nausea			
subjects affected / exposed	2 / 6 (33.33%)	3 / 6 (50.00%)	4 / 14 (28.57%)
occurrences (all)	2	5	4
Odynophagia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Oral pain			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rectal discharge			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	2 / 6 (33.33%)	1 / 6 (16.67%)	2 / 14 (14.29%)
occurrences (all)	5	2	3
Toothache			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Vomiting			
subjects affected / exposed	0 / 6 (0.00%)	4 / 6 (66.67%)	2 / 14 (14.29%)
occurrences (all)	0	9	2
Hepatobiliary disorders			
Bile duct stenosis			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Biliary dilatation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Jaundice			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Jaundice cholestatic			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin and subcutaneous tissue disorders			
PRURITIC LESIONS			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Acne			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Alopecia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Blister			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Dermal cyst			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Dermatitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Dermatitis acneiform			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	3 / 14 (21.43%)
occurrences (all)	2	0	7

Dry skin			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Eczema			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Erythema			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	1	3	0
Erythema nodosum			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Hyperhidrosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Ingrowing nail			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Intertrigo			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Nail disorder			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Night sweats			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Nodular rash			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Onychalgia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Onychoclasia			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0

Pain of skin			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Photosensitivity reaction			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pruritus			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	1	2	0
Pruritus generalised			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Psoriasis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Purpura			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rash			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	2 / 14 (14.29%)
occurrences (all)	0	2	2
Rash erythematous			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rash generalised			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rash maculo-papular			

subjects affected / exposed	2 / 6 (33.33%)	1 / 6 (16.67%)	2 / 14 (14.29%)
occurrences (all)	7	3	2
Rash papular			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Rash pruritic			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	1 / 14 (7.14%)
occurrences (all)	9	2	1
Scab			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin discolouration			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin irritation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin mass			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Skin ulcer haemorrhage			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Toxic skin eruption			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Urticaria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Renal and urinary disorders			

Chronic kidney disease			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Dysuria			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	2	1	0
Glycosuria			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Haematuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Incontinence			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Leukocyturia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Nocturia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pollakiuria			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Proteinuria			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	3	0	0
Renal atrophy			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Renal vein thrombosis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Urinary hesitation			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	0

Urinary incontinence subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 14 (7.14%) 1
Urinary retention subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	1 / 14 (7.14%) 1
Endocrine disorders Hypothyroidism subjects affected / exposed occurrences (all)	3 / 6 (50.00%) 2	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Back pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 1	1 / 14 (7.14%) 1
Bone pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Coccydynia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Flank pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Groin pain subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Intervertebral disc protrusion subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Joint stiffness subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Joint swelling			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Muscle spasms			
subjects affected / exposed	1 / 6 (16.67%)	2 / 6 (33.33%)	0 / 14 (0.00%)
occurrences (all)	1	3	0
Muscle twitching			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal chest pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal discomfort			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal stiffness			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Myalgia			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	4	1	0
Neck pain			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pain in extremity			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	2 / 14 (14.29%)
occurrences (all)	0	1	2
Pain in jaw			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Spondylitis			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Temporomandibular joint syndrome			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Trismus			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Cellulitis			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Conjunctivitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Eye infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Fungal skin infection			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0

Herpes zoster			
subjects affected / exposed	1 / 6 (16.67%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	1	2	0
Kidney infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Laryngitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Lung infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Mastoiditis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Nasal vestibulitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Nasopharyngitis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Onychomycosis			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	1	0	0
Oral candidiasis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Otitis externa			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0

Paronychia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Pneumonia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Postoperative wound infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Rash pustular			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Sepsis			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 6 (0.00%)	1 / 6 (16.67%)	0 / 14 (0.00%)
occurrences (all)	0	1	0
Staphylococcal infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1

Urinary tract infection bacterial subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Viral infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	1 / 6 (16.67%) 2	0 / 14 (0.00%) 0
Wound infection subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Metabolism and nutrition disorders			
Cachexia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Decreased appetite subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 2	2 / 6 (33.33%) 2	2 / 14 (14.29%) 3
Dehydration subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 1	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Failure to thrive subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Hypercholesterolaemia subjects affected / exposed occurrences (all)	1 / 6 (16.67%) 8	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Hyperglycaemia subjects affected / exposed occurrences (all)	2 / 6 (33.33%) 9	1 / 6 (16.67%) 1	6 / 14 (42.86%) 19
Hyperkalaemia subjects affected / exposed occurrences (all)	0 / 6 (0.00%) 0	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Hypertriglyceridaemia subjects affected / exposed occurrences (all)	3 / 6 (50.00%) 21	0 / 6 (0.00%) 0	0 / 14 (0.00%) 0
Hyperuricaemia			

subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypervolaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypocalcaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
Hypoglycaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Hypophosphataemia			
subjects affected / exposed	1 / 6 (16.67%)	0 / 6 (0.00%)	2 / 14 (14.29%)
occurrences (all)	1	0	5
Increased appetite			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Vitamin D deficiency			
subjects affected / exposed	0 / 6 (0.00%)	0 / 6 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Dose Expansion cohort - ES	Dose Expansion cohort - CRPC	Dose Expansion cohort - CLL/SLL
Total subjects affected by non-serious adverse events			
subjects affected / exposed	10 / 10 (100.00%)	12 / 12 (100.00%)	8 / 8 (100.00%)

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Melanocytic naevus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tumour haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tumour necrosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tumour pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vascular disorders			
Arterial disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Deep vein thrombosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Flushing			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Haematoma			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Hot flush			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypertension			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypotension			

subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Orthostatic hypotension			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pallor			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Peripheral coldness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	4 / 10 (40.00%)	3 / 12 (25.00%)	2 / 8 (25.00%)
occurrences (all)	8	4	2
Chest discomfort			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Chills			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cyst			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Discomfort			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Early satiety			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Face oedema			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Facial pain			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Fatigue			
subjects affected / exposed	4 / 10 (40.00%)	10 / 12 (83.33%)	1 / 8 (12.50%)
occurrences (all)	3	16	1
Gait disturbance			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
General physical health deterioration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Influenza like illness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Malaise			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Mucosal inflammation			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	2 / 8 (25.00%)
occurrences (all)	0	1	3
Non-cardiac chest pain			
subjects affected / exposed	2 / 10 (20.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	2	0	1
Oedema peripheral			
subjects affected / exposed	0 / 10 (0.00%)	5 / 12 (41.67%)	2 / 8 (25.00%)
occurrences (all)	0	4	2
Pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Peripheral swelling			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Pyrexia			
subjects affected / exposed	1 / 10 (10.00%)	2 / 12 (16.67%)	5 / 8 (62.50%)
occurrences (all)	1	2	9
Swelling			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Temperature intolerance subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	1 / 8 (12.50%) 1
Tenderness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Social circumstances HEARING IMPAIRMENT subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Reproductive system and breast disorders Cervical polyp subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Gynaecomastia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0
Pelvic pain subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Penile pain subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Vaginal discharge subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Vaginal haemorrhage subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Vulvovaginal swelling subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Respiratory, thoracic and mediastinal disorders			

DYSPNEA ON EXERTION			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Atelectasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Bronchial obstruction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Bronchospasm			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Catarrh			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cough			
subjects affected / exposed	3 / 10 (30.00%)	1 / 12 (8.33%)	3 / 8 (37.50%)
occurrences (all)	4	1	3
Dysphonia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Dyspnoea			
subjects affected / exposed	4 / 10 (40.00%)	3 / 12 (25.00%)	2 / 8 (25.00%)
occurrences (all)	6	3	2
Dyspnoea at rest			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dyspnoea exertional			
subjects affected / exposed	2 / 10 (20.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Epistaxis			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	2 / 8 (25.00%)
occurrences (all)	0	0	0
Haemoptysis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Hiccups			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypoxia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Increased bronchial secretion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Lung infiltration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Nasal congestion			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	2	0	1
Nasal inflammation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Oropharyngeal pain			
subjects affected / exposed	1 / 10 (10.00%)	1 / 12 (8.33%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Paranasal sinus discomfort			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Pharyngeal inflammation			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Pleuritic pain			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	4	0	0
Pneumothorax			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Productive cough			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Pulmonary embolism			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pulmonary oedema			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Respiratory tract congestion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Rhinorrhoea			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	3 / 8 (37.50%)
occurrences (all)	0	0	5
Sputum discoloured			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	2	0	1
Wheezing			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
Abulia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Agitation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Anxiety			
subjects affected / exposed	2 / 10 (20.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Bradyphrenia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0

Confusional state			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Depression			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	1 / 10 (10.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
Irritability			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Nervousness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Personality change			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Restlessness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Sleep disorder			
subjects affected / exposed	0 / 10 (0.00%)	2 / 12 (16.67%)	2 / 8 (25.00%)
occurrences (all)	0	2	3
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Alanine aminotransferase increased			
subjects affected / exposed	1 / 10 (10.00%)	3 / 12 (25.00%)	1 / 8 (12.50%)
occurrences (all)	1	3	1
Amylase increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Aspartate aminotransferase increased			

subjects affected / exposed	2 / 10 (20.00%)	4 / 12 (33.33%)	0 / 8 (0.00%)
occurrences (all)	4	5	0
Bacterial test positive			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Blood albumin decreased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood alkaline phosphatase increased			
subjects affected / exposed	2 / 10 (20.00%)	2 / 12 (16.67%)	0 / 8 (0.00%)
occurrences (all)	1	2	0
Blood bilirubin increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood cholesterol increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 10 (10.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
Blood creatinine increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Blood insulin increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Blood phosphorus increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone decreased			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood triglycerides increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Breath sounds abnormal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
CD4 lymphocytes increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Ejection fraction decreased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Eosinophil count increased			
subjects affected / exposed	0 / 10 (0.00%)	2 / 12 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
Gamma-glutamyltransferase increased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Glucose urine present			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Glycosylated haemoglobin increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Insulin C-peptide increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
International normalised ratio increased			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Lipase increased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	3	0
Lymphocyte count decreased			
subjects affected / exposed	2 / 10 (20.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Neutrophil count decreased			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Platelet count decreased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Tandem gait test abnormal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Thyroxine increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Transaminases increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Weight decreased			
subjects affected / exposed	2 / 10 (20.00%)	3 / 12 (25.00%)	4 / 8 (50.00%)
occurrences (all)	2	5	6
Weight increased			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
White blood cell count decreased			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Injury, poisoning and procedural complications			
Arthropod bite			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Contusion			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Ear injury			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Fall			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Foreign body in eye			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Head injury			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Inappropriate schedule of product administration			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Injury corneal			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Muscle strain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Overdose			
subjects affected / exposed	1 / 10 (10.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	1	1	0
Post procedural discomfort			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Procedural pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Skin laceration subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	1 / 8 (12.50%) 2
Skin wound subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Congenital, familial and genetic disorders Primary immunodeficiency syndrome subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	1 / 8 (12.50%) 1
Cardiac disorders Angina pectoris subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Cardiomyopathy subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Palpitations subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Supraventricular tachycardia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Tachycardia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
MITRAL VALVE DISEASE subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Nervous system disorders Aphasia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Apraxia subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0

Ataxia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Disturbance in attention			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dizziness			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	1 / 8 (12.50%)
occurrences (all)	0	2	1
Dysaesthesia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dysarthria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dysgeusia			
subjects affected / exposed	0 / 10 (0.00%)	2 / 12 (16.67%)	1 / 8 (12.50%)
occurrences (all)	0	2	1
Facial neuralgia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Facial paralysis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Formication			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Headache			
subjects affected / exposed	2 / 10 (20.00%)	2 / 12 (16.67%)	2 / 8 (25.00%)
occurrences (all)	2	2	2
Hemiparesis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hyperaesthesia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Hypersomnia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypoaesthesia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Lethargy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Memory impairment			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Neuralgia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Neuropathy peripheral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Neurotoxicity			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Seizure			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Sensory disturbance			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Sensory loss			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Somnolence			
subjects affected / exposed	3 / 10 (30.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	3	0	0

Syncope			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Taste disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tremor			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Trigeminal nerve paresthesia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Vocal cord paralysis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	5 / 10 (50.00%)	1 / 12 (8.33%)	2 / 8 (25.00%)
occurrences (all)	2	4	3
Eosinophilia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Iron deficiency anaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Leukocytosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Lymphopenia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Neutropenia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	3 / 8 (37.50%)
occurrences (all)	1	0	2
Normocytic anaemia			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Thrombocytopenia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 2	2 / 12 (16.67%) 2	3 / 8 (37.50%) 3
Ear and labyrinth disorders			
Deafness bilateral subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Ear discomfort subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Ear pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	1 / 8 (12.50%) 1
Eustachian tube disorder subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	1 / 8 (12.50%) 1
Hypoacusis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Tinnitus subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	1 / 8 (12.50%) 1
Vertigo positional subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0
Eye disorders			
Blepharitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	1 / 8 (12.50%) 1
Blindness unilateral subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 12 (8.33%) 0	0 / 8 (0.00%) 0
Cataract			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Chorioretinal disorder			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Diplopia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Dry eye			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Eye disorder			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Eye pruritus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Eyelid ptosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Scleral hyperaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Strabismus			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	0 / 10 (0.00%)	2 / 12 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Visual impairment			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0

Abdominal distension			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal pain lower			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Abdominal tenderness			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Anal incontinence			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Anal inflammation			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Anorectal discomfort			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Aphthous ulcer			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Breath odour			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Colitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Constipation			
subjects affected / exposed	3 / 10 (30.00%)	3 / 12 (25.00%)	1 / 8 (12.50%)
occurrences (all)	6	2	1

Dental caries			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Diarrhoea			
subjects affected / exposed	4 / 10 (40.00%)	3 / 12 (25.00%)	4 / 8 (50.00%)
occurrences (all)	8	5	7
Dry mouth			
subjects affected / exposed	3 / 10 (30.00%)	2 / 12 (16.67%)	0 / 8 (0.00%)
occurrences (all)	3	2	0
Dyspepsia			
subjects affected / exposed	0 / 10 (0.00%)	2 / 12 (16.67%)	1 / 8 (12.50%)
occurrences (all)	0	4	2
Dysphagia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Flatulence			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Frequent bowel movements			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Gingival bleeding			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Glossodynia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Haemorrhoids			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Nausea			
subjects affected / exposed	5 / 10 (50.00%)	4 / 12 (33.33%)	3 / 8 (37.50%)
occurrences (all)	6	7	3

Odynophagia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Oral pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Rectal discharge			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rectal haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Stomatitis			
subjects affected / exposed	2 / 10 (20.00%)	4 / 12 (33.33%)	1 / 8 (12.50%)
occurrences (all)	3	5	1
Toothache			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Vomiting			
subjects affected / exposed	3 / 10 (30.00%)	3 / 12 (25.00%)	0 / 8 (0.00%)
occurrences (all)	3	4	0
Hepatobiliary disorders			
Bile duct stenosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Biliary dilatation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hyperbilirubinaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Jaundice			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Jaundice cholestatic			

subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Skin and subcutaneous tissue disorders			
PRURITIC LESIONS			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Acne			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Alopecia			
subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	0 / 12 (0.00%) 0	1 / 8 (12.50%) 1
Blister			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Dermal cyst			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0
Dermatitis			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0
Dermatitis acneiform			
subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 6	0 / 12 (0.00%) 0	1 / 8 (12.50%) 1
Dry skin			
subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	2 / 12 (16.67%) 2	0 / 8 (0.00%) 0
Eczema			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Erythema			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	1 / 8 (12.50%) 2
Erythema nodosum			
subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0

Hyperhidrosis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Ingrowing nail			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	3	0	0
Intertrigo			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Nail disorder			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Night sweats			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	2 / 8 (25.00%)
occurrences (all)	0	0	2
Nodular rash			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Onychalgia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Onychoclasia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Pain of skin			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Photosensitivity reaction			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Pruritus			

subjects affected / exposed	1 / 10 (10.00%)	3 / 12 (25.00%)	1 / 8 (12.50%)
occurrences (all)	2	3	1
Pruritus generalised			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Psoriasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Purpura			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	2
Rash			
subjects affected / exposed	1 / 10 (10.00%)	4 / 12 (33.33%)	3 / 8 (37.50%)
occurrences (all)	1	11	4
Rash erythematous			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rash generalised			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rash macular			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Rash maculo-papular			
subjects affected / exposed	3 / 10 (30.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	5	2	0
Rash papular			
subjects affected / exposed	0 / 10 (0.00%)	2 / 12 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
Rash pruritic			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Scab			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin discolouration			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin fissures			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Skin irritation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Skin mass			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin ulcer haemorrhage			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Toxic skin eruption			
subjects affected / exposed	0 / 10 (0.00%)	2 / 12 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	4	0
Urticaria			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	1 / 8 (12.50%)
occurrences (all)	0	1	2
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	3	0
Dysuria			
subjects affected / exposed	2 / 10 (20.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Glycosuria			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Haematuria			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0

Incontinence			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Leukocyturia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Nocturia			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	1 / 8 (12.50%)
occurrences (all)	0	1	1
Pollakiuria			
subjects affected / exposed	0 / 10 (0.00%)	3 / 12 (25.00%)	0 / 8 (0.00%)
occurrences (all)	0	5	0
Proteinuria			
subjects affected / exposed	1 / 10 (10.00%)	1 / 12 (8.33%)	2 / 8 (25.00%)
occurrences (all)	3	1	4
Renal atrophy			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Renal vein thrombosis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Urinary hesitation			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Urinary incontinence			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Urinary retention			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Musculoskeletal and connective tissue disorders			

Arthralgia			
subjects affected / exposed	0 / 10 (0.00%)	3 / 12 (25.00%)	1 / 8 (12.50%)
occurrences (all)	0	7	1
Back pain			
subjects affected / exposed	0 / 10 (0.00%)	3 / 12 (25.00%)	0 / 8 (0.00%)
occurrences (all)	0	6	0
Bone pain			
subjects affected / exposed	0 / 10 (0.00%)	2 / 12 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Coccydynia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Flank pain			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	2	0
Groin pain			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Intervertebral disc protrusion			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Joint stiffness			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Joint swelling			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Muscle spasms			
subjects affected / exposed	0 / 10 (0.00%)	2 / 12 (16.67%)	2 / 8 (25.00%)
occurrences (all)	0	2	5
Muscle twitching			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Muscular weakness			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0

Musculoskeletal chest pain subjects affected / exposed occurrences (all)	2 / 10 (20.00%) 2	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Musculoskeletal discomfort subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Musculoskeletal pain subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 1	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0
Musculoskeletal stiffness subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Myalgia subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 3	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Neck pain subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Pain in extremity subjects affected / exposed occurrences (all)	1 / 10 (10.00%) 3	1 / 12 (8.33%) 0	0 / 8 (0.00%) 0
Pain in jaw subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Spondylitis subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Temporomandibular joint syndrome subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	1 / 12 (8.33%) 1	0 / 8 (0.00%) 0
Trismus subjects affected / exposed occurrences (all)	0 / 10 (0.00%) 0	0 / 12 (0.00%) 0	0 / 8 (0.00%) 0
Infections and infestations Bacteraemia			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Bronchitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	2
Cellulitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Cystitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Eye infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Folliculitis			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Fungal skin infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Gastroenteritis viral			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	2
Herpes zoster			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	2 / 8 (25.00%)
occurrences (all)	0	0	2
Kidney infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Laryngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Lung infection			

subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Mastoiditis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Nasal vestibulitis			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Nasopharyngitis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	2 / 8 (25.00%)
occurrences (all)	0	0	2
Onychomycosis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Oral candidiasis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Oral herpes			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	2 / 8 (25.00%)
occurrences (all)	0	0	2
Otitis externa			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Otitis media			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Paronychia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Pneumonia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Postoperative wound infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Rash pustular			

subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Respiratory tract infection			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	1	0	1
Sepsis			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Skin infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Staphylococcal infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tooth abscess			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Tooth infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Upper respiratory tract infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	2 / 8 (25.00%)
occurrences (all)	0	1	4
Urinary tract infection bacterial			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Viral infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Wound infection			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Metabolism and nutrition disorders			

Cachexia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Decreased appetite			
subjects affected / exposed	5 / 10 (50.00%)	8 / 12 (66.67%)	2 / 8 (25.00%)
occurrences (all)	7	10	2
Dehydration			
subjects affected / exposed	0 / 10 (0.00%)	2 / 12 (16.67%)	0 / 8 (0.00%)
occurrences (all)	0	3	0
Failure to thrive			
subjects affected / exposed	0 / 10 (0.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	0	1	0
Hypercholesterolaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hyperglycaemia			
subjects affected / exposed	3 / 10 (30.00%)	4 / 12 (33.33%)	1 / 8 (12.50%)
occurrences (all)	4	8	7
Hyperkalaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Hypertriglyceridaemia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Hyperuricaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypervolaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypoalbuminaemia			
subjects affected / exposed	2 / 10 (20.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	2	0	0
Hypocalcaemia			
subjects affected / exposed	1 / 10 (10.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	1	0	0

Hypoglycaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypokalaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hypomagnesaemia			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0
Hyponatraemia			
subjects affected / exposed	1 / 10 (10.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	1	0	0
Hypophosphataemia			
subjects affected / exposed	1 / 10 (10.00%)	1 / 12 (8.33%)	0 / 8 (0.00%)
occurrences (all)	3	1	0
Increased appetite			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	1 / 8 (12.50%)
occurrences (all)	0	0	1
Vitamin D deficiency			
subjects affected / exposed	0 / 10 (0.00%)	0 / 12 (0.00%)	0 / 8 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Dose Expansion cohort - BA/Food Effect		
Total subjects affected by non-serious adverse events			
subjects affected / exposed	12 / 12 (100.00%)		
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Cancer pain			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	2		
Melanocytic naevus			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Tumour haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Tumour necrosis			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Tumour pain			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	0		
Vascular disorders			
Arterial disorder			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Deep vein thrombosis			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	1		
Flushing			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Haematoma			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hot flush			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hypertension			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hypotension			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Orthostatic hypotension			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Pallor			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Peripheral coldness			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		

General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	4 / 12 (33.33%)		
occurrences (all)	7		
Chest discomfort			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Chills			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Cyst			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Discomfort			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Early satiety			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Face oedema			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Facial pain			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Fatigue			
subjects affected / exposed	7 / 12 (58.33%)		
occurrences (all)	10		
Gait disturbance			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
General physical health deterioration			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Influenza like illness			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Malaise			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Mucosal inflammation			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Non-cardiac chest pain			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	2		
Oedema peripheral			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Peripheral swelling			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	2		
Pyrexia			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Swelling			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Temperature intolerance			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Tenderness			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Social circumstances			
HEARING IMPAIRMENT			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		

Reproductive system and breast disorders			
Cervical polyp			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Gynaecomastia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pelvic pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Penile pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Vaginal discharge			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Vaginal haemorrhage			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Vulvovaginal swelling			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Respiratory, thoracic and mediastinal disorders			
DYSPNEA ON EXERTION			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Atelectasis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Bronchial obstruction			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Bronchospasm			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Catarrh			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Chronic obstructive pulmonary disease			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Cough			
subjects affected / exposed	4 / 12 (33.33%)		
occurrences (all)	3		
Dysphonia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dyspnoea			
subjects affected / exposed	5 / 12 (41.67%)		
occurrences (all)	6		
Dyspnoea at rest			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dyspnoea exertional			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Epistaxis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Haemoptysis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Hiccups			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Hypoxia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Increased bronchial secretion			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		

Lung infiltration			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Nasal congestion			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Nasal inflammation			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Oropharyngeal pain			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Paranasal sinus discomfort			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pharyngeal inflammation			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pleuritic pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pneumothorax			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Productive cough			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pulmonary embolism			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pulmonary oedema			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Respiratory tract congestion			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		

Rhinorrhoea			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Sputum discoloured			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Wheezing			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Psychiatric disorders			
Abulia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Agitation			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Anxiety			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Bradyphrenia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Confusional state			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Depression			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	3		
Insomnia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Irritability			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Nervousness			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Personality change			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Restlessness			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Sleep disorder			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Investigations			
Activated partial thromboplastin time prolonged			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Alanine aminotransferase increased			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Amylase increased			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Aspartate aminotransferase increased			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	2		
Bacterial test positive			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood albumin decreased			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Blood alkaline phosphatase increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood bilirubin increased			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood cholesterol increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood creatine phosphokinase increased			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Blood creatinine increased			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	3		
Blood insulin increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood lactate dehydrogenase increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood phosphorus increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood thyroid stimulating hormone decreased			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	0		
Blood thyroid stimulating hormone increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blood triglycerides increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Breath sounds abnormal			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
CD4 lymphocytes increased			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Ejection fraction decreased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Eosinophil count increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Gamma-glutamyltransferase increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Glucose urine present			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Glycosylated haemoglobin increased			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Insulin C-peptide increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
International normalised ratio increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Lipase increased			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Lymphocyte count decreased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Neutrophil count decreased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Platelet count decreased			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Tandem gait test abnormal			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Thyroxine increased			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	0		
Transaminases increased			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Weight decreased			
subjects affected / exposed	5 / 12 (41.67%)		
occurrences (all)	7		
Weight increased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
White blood cell count decreased			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Injury, poisoning and procedural complications			
Arthropod bite			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Contusion			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Ear injury			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Fall			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Foreign body in eye			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Head injury			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Inappropriate schedule of product administration			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Injury corneal			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Muscle strain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Overdose			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Post procedural discomfort			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Procedural pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Skin laceration			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Skin wound			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Congenital, familial and genetic disorders			
Primary immunodeficiency syndrome			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Cardiac disorders			

Angina pectoris			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Cardiomyopathy			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Palpitations			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Supraventricular tachycardia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Tachycardia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
MITRAL VALVE DISEASE			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Nervous system disorders			
Aphasia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Apraxia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Ataxia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Disturbance in attention			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dizziness			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	4		
Dysaesthesia			

subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Dysarthria			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dysgeusia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Facial neuralgia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Facial paralysis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Formication			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Headache			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Hemiparesis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hyperaesthesia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Hypersomnia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hypoaesthesia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Lethargy			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Memory impairment			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Neuralgia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Neuropathy peripheral			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	0		
Neurotoxicity			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Paraesthesia			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	3		
Seizure			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Sensory disturbance			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Sensory loss			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Somnolence			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Syncope			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Taste disorder			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Tremor			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Trigeminal nerve paresis			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Vocal cord paralysis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	7		
Eosinophilia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Iron deficiency anaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Leukocytosis			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	3		
Lymphopenia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Neutropenia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Normocytic anaemia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Thrombocytopenia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Ear and labyrinth disorders			
Deafness bilateral			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Ear discomfort			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Ear pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Eustachian tube disorder			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hypoacusis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Tinnitus			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Vertigo positional			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Eye disorders			
Blepharitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blindness unilateral			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Cataract			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Chorioretinal disorder			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Diplopia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Dry eye			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	0		

Eye disorder			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Eye pruritus			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Eyelid ptosis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Scleral hyperaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Strabismus			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	0		
Vision blurred			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Visual impairment			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Abdominal distension			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Abdominal pain			
subjects affected / exposed	4 / 12 (33.33%)		
occurrences (all)	4		
Abdominal pain lower			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Abdominal pain upper			

subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	1		
Abdominal tenderness			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	0		
Anal incontinence			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Anal inflammation			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Anorectal discomfort			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Aphthous ulcer			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Breath odour			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Colitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Constipation			
subjects affected / exposed	4 / 12 (33.33%)		
occurrences (all)	5		
Dental caries			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Diarrhoea			
subjects affected / exposed	7 / 12 (58.33%)		
occurrences (all)	13		
Dry mouth			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Dyspepsia			

subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Dysphagia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Flatulence			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Frequent bowel movements			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Gingival bleeding			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Glossodynia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Haemorrhoids			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Nausea			
subjects affected / exposed	10 / 12 (83.33%)		
occurrences (all)	10		
Odynophagia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Oral pain			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Rectal discharge			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Rectal haemorrhage			

<p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 12 (0.00%)</p> <p>0</p>		
<p>Stomatitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>4 / 12 (33.33%)</p> <p>9</p>		
<p>Toothache</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 12 (8.33%)</p> <p>1</p>		
<p>Vomiting</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>6 / 12 (50.00%)</p> <p>10</p>		
<p>Hepatobiliary disorders</p> <p>Bile duct stenosis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Biliary dilatation</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Hyperbilirubinaemia</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Jaundice</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Jaundice cholestatic</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 12 (0.00%)</p> <p>0</p> <p>0 / 12 (0.00%)</p> <p>0</p> <p>1 / 12 (8.33%)</p> <p>1</p> <p>0 / 12 (0.00%)</p> <p>0</p> <p>1 / 12 (8.33%)</p> <p>1</p>		
<p>Skin and subcutaneous tissue disorders</p> <p>PRURITIC LESIONS</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Acne</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p> <p>Alopecia</p>	<p>0 / 12 (0.00%)</p> <p>0</p> <p>0 / 12 (0.00%)</p> <p>0</p>		

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Blister			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dermal cyst			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dermatitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dermatitis acneiform			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Dry skin			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	3		
Eczema			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Erythema			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Erythema nodosum			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hyperhidrosis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Ingrowing nail			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Intertrigo			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Nail disorder			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Night sweats			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Nodular rash			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Onychalgia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Onychoclasia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pain of skin			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Palmar-plantar erythrodysaesthesia syndrome			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Photosensitivity reaction			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pruritus			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	5		
Pruritus generalised			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	3		
Psoriasis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Purpura			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		

Rash			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	5		
Rash erythematous			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Rash generalised			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Rash macular			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Rash maculo-papular			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	2		
Rash papular			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Rash pruritic			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Scab			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Skin discolouration			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Skin fissures			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Skin irritation			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Skin lesion			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	0		

Skin mass			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Skin ulcer haemorrhage			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Toxic skin eruption			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Urticaria			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Renal and urinary disorders			
Chronic kidney disease			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Dysuria			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Glycosuria			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Haematuria			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Incontinence			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Leukocyturia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Nocturia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pollakiuria			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Proteinuria			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Renal atrophy			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Renal vein thrombosis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Urinary hesitation			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Urinary incontinence			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Urinary retention			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	0		
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Back pain			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	3		
Bone pain			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	0		
Coccydynia			

subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Flank pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Groin pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Intervertebral disc protrusion			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Joint stiffness			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Joint swelling			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Muscle spasms			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Muscle twitching			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Muscular weakness			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	0		
Musculoskeletal chest pain			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Musculoskeletal discomfort			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Musculoskeletal pain			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	1		
Musculoskeletal stiffness			

subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Myalgia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Neck pain			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pain in extremity			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Pain in jaw			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Spondylitis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Temporomandibular joint syndrome			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Trismus			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Infections and infestations			
Bacteraemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Bronchitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Cellulitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Conjunctivitis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		

Cystitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Eye infection			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Folliculitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Fungal skin infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Gastroenteritis viral			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Herpes zoster			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Kidney infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Laryngitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Lung infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Mastoiditis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Nasal vestibulitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Nasopharyngitis			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		

Onychomycosis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Oral candidiasis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Oral herpes			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Otitis externa			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Otitis media			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Paronychia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Pneumonia			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	3		
Postoperative wound infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Rash pustular			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Respiratory tract infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Sepsis			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Skin infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		

Staphylococcal infection			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Tooth abscess			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Tooth infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Upper respiratory tract infection			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Urinary tract infection			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	2		
Urinary tract infection bacterial			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Viral infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Wound infection			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Metabolism and nutrition disorders			
Cachexia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Decreased appetite			
subjects affected / exposed	8 / 12 (66.67%)		
occurrences (all)	8		
Dehydration			
subjects affected / exposed	4 / 12 (33.33%)		
occurrences (all)	5		
Failure to thrive			

subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Hypercholesterolaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hyperglycaemia			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	4		
Hyperkalaemia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Hypertriglyceridaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hyperuricaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hypervolaemia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Hypoalbuminaemia			
subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Hypocalcaemia			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Hypoglycaemia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Hypokalaemia			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	4		
Hypomagnesaemia			
subjects affected / exposed	3 / 12 (25.00%)		
occurrences (all)	2		
Hyponatraemia			

subjects affected / exposed	2 / 12 (16.67%)		
occurrences (all)	2		
Hypophosphataemia			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	1		
Increased appetite			
subjects affected / exposed	0 / 12 (0.00%)		
occurrences (all)	0		
Vitamin D deficiency			
subjects affected / exposed	1 / 12 (8.33%)		
occurrences (all)	0		

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported